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Abstract 
 The aim of this thesis is to demonstrate how the use of administrative health 
data (AHD) has evolved over time to be a valuable resource for quantifying disease 
burden. AHD are defined as data routinely collected for the purposes of payment, 
monitoring, priority setting, and evaluation of the provision of health services. While 
the primary purpose of AHD is not research, and researchers typically do not have a 
direct role in their collection, they represent a rich source of data for secondary 
analyses.  
The thesis presents and critiques 12 peer-reviewed publications to demonstrate 
how the use of AHD has evolved for better understanding the burden of disease. Each 
publication shows a natural evolution in thinking, and sophistication of methods that 
help to illustrate how secondary data can be used to augment primary data collection 
methods. The development of evidence using different methods, particularly when 
there are consistent results, works to strengthen our understanding of any given health 
issue. 
The thesis defines AHD, as well as its strengths and limitations, and how these 
data can be considered ‘big data’. Next, historical developments on secondary use and 
AHD are provided starting with the work of John Graunt, and ending with the present 
author.  
The value of AHD is explored critically through the following themes: role of 
mortality and hospitalisation data; development of algorithms for improving the 
accuracy of AHD for determining the presence of disease (case definition algorithms); 
strength and value of longitudinal designs; identification of rare health events; 
assessing the burden of co-morbidities; assessing health outcomes; and finally how 
AHD can support policy development. Future directions for research are highlighted, as 
well as how AHD can be used to inform policy, resource allocation, and practice.   
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Chapter 1: Introduction 
1.1 Aims of the Thesis 
Administrative health data (AHD) are data routinely collected as part of the 
operation of the healthcare system. The overall aim of the thesis is to present and 
critique how AHD has evolved to become a valuable resource for health services 
research in general, and the quantification of disease burden specifically. The thesis 
will achieve this aim through the presentation of 12 papers, for which the present 
author was either the sole or co-author. The papers presented as part of this thesis 
were chosen from 139 papers authored or co-authored by the current author covering 
the period 1990 to 2014. Each paper was selected to exhibit a natural evolution in 
thinking with an emphasis on applied studies designed with a propensity for 
quantifying disease burden in order to inform and evaluate health policy, programs, 
practice, outcomes, and risk assessment.  
Historically disease burden was quantified using mortality rates, but has 
evolved to use other metrics such as incidence, prevalence, disability adjusted life 
years, potential years of life lost, and others (Murray, 1994). It has been suggested that 
measures used to quantify the burden of disease should be done to: aid in priority 
setting for service delivery; set research priorities; identify high risk or high need 
populations; and provide evidence for measuring the impact of interventions (Murray, 
1994). 
The thesis will present and critique 12 papers in the context of when each was 
published, highlight unique approaches, and contributions for the use of AHD for 
quantifying disease burden will be demonstrated. Given that the papers span a 25-year 
period, earlier papers may appear somewhat simplistic in approach or content, but 
were unique to their time. In addition, it will describe and critique the methods used, 
compare and contrast results from other studies that used primary or secondary 
approaches. Issues identified through the critique may be specific to an individual 
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paper or may be more general across multiple papers. The specific issues identified for 
an individual paper are captured as part of the critical commentary of that chapter. 
However, where the issues are applicable to multiple papers, they are addressed in 
both the final summative methodological critique in Chapter 9, and concluding sections 
of the relevant chapter. Ten of the 12 papers are based exclusively on data from the 
province of Alberta, Canada, and the results will be placed into both the context of 
Canadian and international studies. 
Primary approaches involve the collection of data by the researcher with a 
specific hypothesis that is often generated through a review of prior work. Secondary 
approaches draw upon already available data and information that was derived from 
primary research or administrative processes (Glass, 1976). While the studies included 
have applicability to the use of AHD broadly, they were conducted in Canada so an 
understanding of the Canadian context is important. International comparators will be 
used as appropriate.  
In Canada, each province and territory has responsibility for the delivery of 
healthcare services, with the federal government being responsible for health services 
for the military, federal inmates, First Nations living on reserves, those living north of 
the 60th parallel, and international points of entry to the country (Shah, 1998). Within 
Canada, healthcare services are publicly administered and funded, and universally 
available to all residents (Baumgart, 1992; Shah, 1998). As part of administering the 
publicly funded healthcare system, each province and territory maintains a number of 
population-based AHD sources. These data have value for understanding, funding, and 
evaluating the healthcare system, as well as supporting research. 
The thesis will exhibit the value of routinely collected mortality data to describe 
geographic and temporal differences across provinces in Canada leading to the 
development of hypotheses on aetiological factors. Next, the formulation of 
hypotheses will evolve to the development and use of AHD-based case definition 
algorithms for improving the accuracy of identifying disease states, use of cross-
sectional and longitudinal designs, and how linkage of multiple databases can provide 
 2 
accurate epidemiological measures. The thesis will also highlight how the results have 
direct relevance to health services and outcomes research, applied research, practice, 
and health policy development. 
1.2 Structure of the Thesis 
Chapter 1 provides the overall aim of the thesis and general information on the 
topics to be explored in more depth throughout the thesis. Chapter 2 will focus on 
administrative health data. It provides a definition, highlights strengths and 
weaknesses of this type of data source for research, and highlights historical 
developments.  
Chapters 3 through 8 are organized to highlight early contributions and the 
evolution in the sophistication of the use of AHD for quantifying disease burden. 
Chapter 3 focuses on mortality and hospitalisation data, and provides a critique of 
strengths, limitations, and value of routinely collected data for describing the 
distribution of disease, and for developing aetiological hypotheses. 
Chapter 4 introduces the concept of developing case definitions for attributing 
a disease state to a person as a means of providing more accurate estimates of 
incidence and prevalence of disease. The Chapter addresses issues of concern related 
to the ability to generate reliable and valid epidemiological measures using AHD, as 
well as the importance of understanding the sensitivity and specificity of any definition 
created.  
Chapter 5 focuses on the value of longitudinal designs and how AHD can be 
used as an efficient means of following large cohorts of individuals. Chapter 6 explores 
the value of AHD for assessing the prevalence of rare conditions and critiques the use 
of AHD for assessing comorbidities.  
Chapter 7 appraises AHD for assessing health outcomes and risk. This includes a 
critical commentary of the methods and interpretations. Three examples are provided: 
1) parental ancestry as a risk factor for multiple sclerosis (MS); 2) MS prevalence 
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among First Nations people; and 3) febrile seizure risk following the introduction of a 
new vaccine. 
The contribution of research using AHD for policy development is described in 
Chapter 8. The example provided looks at the impact of an immunisation program for 
chickenpox on the rates of shingles.  
Chapter 9 provides an overall critique of the study designs used across all 12 
publications. Chapter 10 presents a summary, conclusions, and recommendations for 
future research. It highlights the role of AHD in understanding the burden of illness, 
and lays out options for research to further understand the value these data can 
provide.  
The next chapter will discuss the concept of burden of illness, definition of AHD 
including its strengths, limitations, and history.  
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Chapter 2: Administrative Health Data 
2.1 Introduction 
 This chapter will provide a brief overview of administrative health data and its 
history. The narrative will not be exhaustive, but rather will focus on key 
developments. Also, given the papers included in this thesis are based on Canadian 
work, the historical advancement of the use of administrative data will end with a 
focus on Canadian studies as a means of providing a relevant context for this thesis and 
the papers included. Prior to providing an overview of AHD, the concept of burden of 
illness will first be explored, and placed into the context of this thesis.  
2.1.1 Burden of Illness 
 Last (2007) defines burden of disease as: 
“The amount of ill health from a given cause (disease, injury, cause of disease, 
or risk factor) in a population of interest.” (p. 46). 
While there are numerous measures such as incidence, prevalence, mortality, disability 
adjusted life years,  and potential years of life lost are available for measuring aspects 
of burden, an overarching conceptual framework is lacking (Pinheiro et al., 2011). 
However, Pinheiro et al. (2011) have suggested that a framework would include 
targeting the consequences of disease events, may include metrics related to non-
health events such as social and economic impacts, and is related to populations or 
groups rather than on individuals. In general, assessing burden of illness can be 
considered a means of determining the impact of disease events on all aspects of 
human life (Pinheiro et al., 2011).  
 The control of mortality has been considered a paramount goal in policy and 
practice (Sullivan, 1966). Conceptually, this was based on the assumption that changes 
in mortality were indicative of changes in other aspects of health. Measures based on 
mortality data have been the cornerstone for assessing burden (Devleesschauwer et 
al., 2014). However, with increasing importance of non-communicable diseases death-
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related statistics are becoming increasingly inaccurate measures of the overall health 
status of the population (Pinheiro et al., 2011). 
With mortality due to infectious diseases being replaced more and more by 
chronic, or non-communicable, conditions, other metrics of burden are required to 
avoid biasing our understanding of the health of the population. An understanding of 
the burden of disease provides the evidence needed to promote, enhance and protect 
the health of a population through policy and practice, and the metrics to support any 
actions need to be robust and relevant (Murray, 1994; Devleesschauwer et al., 2014).  
Actions taken, whether direct or indirect, aimed at improving the health and 
health needs of the population need to be based on reliable estimations on disease 
burden and risk (Devleesschauwer et al., 2014). Actions also need to be evaluated to 
ensure burden is reduced and not increased. Within the context of this thesis, burden 
of illness will not be considered as a single metric or index. Rather, it will focus on the 
evolution of the use of AHD to quantify aspects of burden and demonstrate the value 
of AHD in this endeavour. 
2.2 Administrative Health Data Defined 
Administrative health data (AHD) are routinely collected for the purpose of 
payment, monitoring, planning, priority setting, and evaluation of the provision of 
health services (Kreyenfeld & Wilekens, 2015; Virnig & McBean, 2001). The primary 
purpose of AHD is not research. However, AHD can be a rich source of data to support 
secondary analyses. Research using these data is considered secondary use when the 
researcher was not directly involved in the design or collection of the data, nor was the 
data collected for a specific research purpose (Potvin & Champagne, 1986; Stewart & 
Kamins, 1993). 
The use of AHD for research can be viewed as adding to, rather than replacing, 
other options for data collection and research, such as randomized controlled trials 
(RCTs), surveys, case-control or cohort studies, meta-analyses, reviews, or 
observational studies. Each of these data collection methods has its strengths and 
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weaknesses. For example, RCTs which are regarded as a gold standard in healthcare 
research (Evans, 2003) tend to have stringent inclusion criteria with their findings 
driven by the protocol, unknown impacts of violations to the protocol, limited sample 
sizes, and relatively short duration of follow-up, all of which can limit generalisability of 
their findings (Cartwright & Munro, 2010). It is not the use of primary or secondary 
approaches that is important, but rather the use of an appropriate method to address 
a given research question. The strengths and limitations of AHD are discussed in the 
next section. 
2.3 Strengths and Limitations of Administrative Health Data 
2.3.1 Administrative Health Data Strengths 
Like any source of data, AHD has its strengths and limitations, and the use of 
the data should be done with an understanding of when the data will work and when 
other strategies are required. The strengths of AHD data over primary data collection 
for research are: they are population-based; data collection is nonintrusive as it can be 
obtained without contacting individuals directly; there is no recall bias, information is 
readily available; collection and use is cost-effective; longer durations of follow-up are 
possible; multiple databases can generally be linked together; data are usually updated 
in a systematic and regular manner; and large sample size (Bright et al., 1989; 
Chowdhury & Hemmelgarn, 2015). Also, the use of AHD, similar to that of a naturalistic 
observational study, can be used to monitor ‘real-life’ interactions with the healthcare 
system (Gallagher, 2004). This allows for a relatively inexpensive and efficient way for 
assessing the effectiveness of interventions, and to determine if they should continue 
or if further study is needed (Gallagher, 2004). While AHD have a number of strengths 
that make their use in research attractive, AHD also have limitations that need to be 
considered prior to use. 
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2.3.2 Administrative Health Data Limitations 
Limitations of AHD include: lack of information on socio-economic status; case 
ascertainment is based on utilization of services which may be independent of disease 
incidence; prevalence, or severity; the researcher was not involved in the design of 
collection of the data; data privacy and protection issues need to be addressed; 
accuracy and precision of the data cannot always be confirmed; large sample size 
leading to statistically significant, but clinical or policy irrelevant findings; policies on 
reporting or reimbursement may lead to biased case ascertainment; and researchers 
are dependent on administrative authorities for access (Chowdhury & Hemmelgarn, 
2015; Ray, 1997).  
AHD generally do not include detailed clinical information such as blood 
pressure measures, or physical measurements like height, weight, and waist 
circumference. These may be captured within electronic medical records, but within 
the Canadian context these data are not generally available at the population level. The 
presence or absence of detailed clinical information varies by jurisdiction. These data 
are also generally missing information on patient behaviours such as drinking, smoking, 
and physical activity (Chowdhury & Hemmelgarn, 2015). Social environment factors 
such as family structure, stability, size, culture, ethnicity, and other attributes tend to 
also be missing from AHD. In essence, AHD provides a breadth of data, but is generally 
lacking depth.  
2.4 Administrative Health Data and Big Data 
 In 1997, Cox and Ellsworth coined the term Big Data. They described the 
problem of increasing amounts of data taxing the ability of computers in the areas of 
main memory, processing, and storage. Since this time the concept has expanded to 
include structured and unstructured data, and is essentially inclusive of any digital 
storage regardless of type. Definitions of big data tend to focus on three key attributes: 
high volumes of data, high velocity, and high variety (Dutcher, 2014). To land on a 
more descriptive definition of big data, Dutcher (2014) surveyed 43 thought leaders 
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from multiple disciplines asking them how they would define the term big data. There 
were a variety of answers with a number of common themes. One definition appeared 
to particularly represent the wide array of responses: 
“While the use of the term is quite nebulous and is often co-opted for other 
purposes, I’ve understood ‘big data’ to be about analysis for data that’s really 
messy or where you don’t know the right questions or queries to make – 
analysis that can help you find patterns, anomalies, or new structures amidst 
otherwise chaotic or complex data points.” (para. 5). 
 
Based on the above definition, AHD can be considered a form of big data. 
Mackie et al. (2015) have cautioned that big data will likely not solve many 
epidemiological questions, and that consideration will need to be given to how to deal 
with ‘messy’ data. Also, that AHD may be limited in what it can contribute to big data 
given the need to protect the confidentiality of data. Aside from concerns with issues 
of confidentiality, Dixon et al. (2013) argued for the need to put in place strategies to 
ensure the integrity and quality of big data, regardless of its source. They contended 
that AHD may not be robust enough to support all the intended uses proposed by 
decision makers, and that the implementation of good data quality practices can work 
to improve the value of these data for decision making. However, Raghupathi and 
Raghupathi (2014) argued that analytic techniques used for big data could be applied 
to the healthcare arena offering significant benefits in the areas of clinical operations, 
research and development, public health, evidence-based medicine, genomic analysis, 
fraud analysis, device/remote monitoring, and patient profile analytics. 
2.5 Administrative Health Data Historical Developments 
2.5.1 John Graunt and the Bills of Mortality 
The value of routinely collected health information came about in 1532 in 
London when the town council started to keep a count of the number of people dying 
as a result of the plague (Choi, 2012; Rothman, 1996). The accounting was done using 
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what were referred to as the Bills of Mortality, which were weekly mortality statistics 
used to monitor burials.  
The Bills were collected off and on for more than a century, but never 
systematically examined until the 1600s (Choi, 2012). In 1662, the English haberdasher 
John Graunt, considered to be one of the first demographers, published a book titled 
Natural and political observations made upon the bills of mortality (Choi, 2012; 
Rothman, 1996). This marked the first comprehensive analysis and interpretation of 
routinely collected health information.  
Graunt demonstrated the value of examining data from a perspective different 
from the original reason for collection. In essence, creating the concept of secondary 
data analysis (Rothman, 1996). Graunt also explored the data without a clear 
hypothesis using what is referred to as exploratory data analysis (Tukey, 1977). Graunt 
allowed the data to guide him on a journey of discovery. The collection of mortality 
data on frequency and cause evolved over the coming centuries, and remains a major 
source of evidence for understanding the health status of a population. 
2.5.2 Understanding Burden of Disease 
A number of notable individuals continued to expand upon Graunt’s early work 
showing the value of mortality data for not only understanding population health, but 
also to inform and advocate for action. For example, Sir Edwin Chadwick highlighted a 
strong association between poverty and poor health outcomes in London. This resulted 
in reforms to the Poor Law leading to the emergence of the modern welfare state, as 
well as the passing of the 1848 Public Health Act (Choi, 2012). 
One of the most noteworthy contributions to the use of mortality data came 
from William Farr. Farr worked at the General Register Office for 41 years (1828 to 
1879) where he started the practice of collecting and analysing vital statistics on a 
routine basis (Choi, 2012). Not only did it include routinely collecting, analysing, and 
disseminating data on deaths, but also the development of standardized processes of 
collection making the data easier to collect and interpret. 
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Mortality data has been the cornerstone for estimating the health of the 
population. It was used for centuries as the only reliable information available. 
However, it is limited for developing health policy and informing practice 
(Devleesschauwer et al., 2014). Other metrics of burden are required to avoid biasing 
our understanding of population health. To be useful, metrics of the burden of disease 
need to be robust and relevant as they provide evidence to promote, enhance, and 
protect population health through policy and practice (Devleesschauwer et al., 2014; 
Murray, 1994). The quantification of disease burden carries an ethical dimension as it 
informs priorities for resource allocations (Murray, 1994).  
2.5.3 Administrative Health Data For Health System Planning 
Moving ahead, to the twentieth century, Rosenfeld et al. (1957) used 
administrative data to assess the need for general hospital care as well as reasons for a 
prolonged hospital stay. Alderson (1976) reviewed the computing policies of the 
National Health Service in the United Kingdom (UK). He argued the value of a reliable 
computing infrastructure as a key component of decision-making. This included the 
concept of a master patient index to allow for accurate identification of individual 
patients. Prior to this, it was only possible to count events with no ability to understand 
the number of people represented by those counts. While not mentioned explicitly by 
Alderson, it also set the stage for ensuring it was possible to link records reliably across 
data sources. 
In 1973, Wennberg and Gittlesohn highlighted wide geographic variations in the 
use of high cost medical procedures. Where a person lived appeared to determine 
what types of services would be available. However, the geographic areas responsible 
for the highest health care expenditures did not necessarily have the best health 
outcomes. While their work had clear policy implications for resource allocations and 
monitoring health system performance, it is the concept of using AHD to describe the 
‘real-world’ that represented an important contribution to the evolving use of AHD. 
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 Roos (1989) used AHD as a way to control for case severity when trying to 
understand health service utilisation patterns. Roos combined hospitalisation and 
physician claims data, and then compared with self-reported data. AHD outperformed 
self-report data when the outcomes of interest were admission to a hospital or nursing 
home, or mortality, showing AHD were potentially valuable for the assessment of 
outcomes. The value of AHD was becoming increasingly evident from a health system 
planning perspective, but it was unknown how, or if, these data could be used to 
understand the health of the population.  
Before considering the use of AHD for estimating measures like incidence and 
prevalence, it is important to understand the properties of the data, and if the data are 
robust enough to support this purpose. A number of issues need to be considered 
when using AHD for research. A single diagnostic code could be part of describing 
signs, interpreting a diagnostic test, a confirmed diagnosis, or an error in coding (Koran, 
1975; Roos et al., 1982). The data may have factual errors that result from the methods 
used by clinicians to assess and diagnose their patients, meaning that the data may be 
an accurate representation of an error made in clinical practice. Unfortunately, it is not 
always possible to review all the evidence used in the clinical decision making process 
given the cost and logistics involved. In other words, an understanding of how a given 
health system and its professionals operate is important to understanding and using 
data derived by the system. 
2.5.5 Administrative Health Data for Estimating Disease Burden in Canada 
Turning to the Canadian context, the Nova Scotia-Saskatchewan Cardiovascular 
Disease Epidemiology Group (1989) linked data from inpatient records with vital 
statistics death registration data in order to estimate the incidence of acute myocardial 
infarction (AMI). The study was one of the first in Canada to look at the data with the 
explicit purpose of assessing the incidence of a health event. The authors concluded 
that linked AHD could be used to assess geographic distribution and temporal trends. 
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Young et al. (1991) conducted a pilot study, to estimate the burden of diabetes 
mellitus in Manitoba. The authors used five years of data to estimate incidence and 
prevalence, and then compared their results with three self-report sources – the 1978 
Canadian Health Survey, 1985 Canadian General Social Survey, and the United States 
National Health and Nutrition Examination Survey II. Estimates derived using AHD were 
comparable to self-report data, leading the researchers to conclude that AHD was a 
potential data source for epidemiological studies. 
To this point, few studies looked at AHD as a potential source for the 
quantification of disease burden. They had been focused on service delivery patterns, 
health services research, funding allocations, and health policy development. It was 
generally not known if AHD could be used to provide accurate estimations of disease 
burden.  
This was the case until the mid-1990s when Svenson et al. (1993; 1994) used 
AHD to estimate the prevalence of Parkinson’s disease (PD) and multiple sclerosis (MS) 
in the province of Alberta using a population-based cohort design. As these were the 
first studies in Canada to use AHD to estimate prevalence of MS and PD, there were no 
other similar AHD-based studies from which comparisons could be made. However, 
prevalence estimates were similar, but tended to be lower, than other studies at that 
time suggesting AHD-derived estimates were likely to undercount cases (Rajput, 1992; 
Svenson et al., 1993; Warren & Warren, 1992, 1993). In 1993, Manfreda et al. 
examined physician records in order to estimate the prevalence of asthma, and the 
possibility for diagnostic exchange, in the province of Manitoba. Manfreda et al. (1993) 
found that there did appear to be evidence of a change in the use of the diagnostic 
codes that could influence prevalence estimation. This demonstrated that practice 
patterns play a role, and need to be understood when using AHD.  
As the 1990s advanced, the number of Canadian papers using AHD increased 
substantially creating a need to better understand the validity of the data. In 1997, 
Robinson et al. reported results from a linkage of survey data with AHD in Manitoba 
concluding that using a single diagnostic code from AHD may increase the inclusion of 
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false positive cases, however, the use of a more stringent case definition increased the 
false negative error to a greater degree. The authors failed to provide performance 
metrics such as sensitivity, specificity, or predictive values, but did use Kappa statistics 
to assess agreement between the sources. In principle, their study was focused on 
congruence between data sources more so then on the validity of AHD. 
The research demonstrating the value of AHD for estimating incidence and 
prevalence resulted in work to validate approaches to better understand the sensitivity 
and specificity of any approach used (Lacasse et al., 2012; Marrie et al., 2013; 
Southern, et al., 2010; To et al., 2006). Also, AHD became the backbone for the 
surveillance of chronic diseases in Canada (Clottey et al., 2001; James et al., 2004; Lix et 
al., 2008). More recent work, done within the context of the Canadian healthcare 
system, has used increasingly sophisticated methods and a move to assessing 
comorbidities and health outcomes (Patten et al., 2007; MacDonald et al., 2014; 
Marrie et al., 2013; Yurkovich et al., 2015).  
2.6 Summary 
The use of AHD has evolved from being used to reimburse health care providers 
and allocate funding, to a better understanding of the operation of the health care 
system, policy development, resource allocation, accountability, and more recently, for 
assessing the health of the population. Prior to 1990, AHD was rarely used to estimate 
disease prevalence or incidence. This represented a gap making it clear that there was 
an opportunity to explore how AHD could address the dearth of information on disease 
burden. Work of the present author, and others, began to show that the creative use 
of AHD could be valuable as a means of better understanding health burden. 
Chapters 3 through 8 will provide a critical appraisal of the 12 papers included 
in this thesis. They will highlight the study design, findings, strengths, limitations, and 
implications as they relate to the use of AHD for the quantification of disease burden.  
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Chapter 3: Role of Mortality and Hospitalisation Data 
3.1 Introduction 
Mortality data represent one of the few data sources collected in virtually all 
countries and have been a mainstay for determining health priorities, and 
understanding population health for hundreds of years (Devleesschauwer et al., 2014). 
Hospitalisation data has been used primarily for resource allocation, and at times 
disease burden, though its history is much shorter. This chapter will provide a critique 
of Publications 1 (Svenson, 1990) and 2 (Svenson, 1991) with a focus on the value of 
mortality and hospitalisation data for assessing disease burden. Both studies focused 
on the geographic distribution of Parkinson’s disease (PD) (Svenson, 1990; Svenson, 
1991). A cross-sectional study design was used for both, and the critique will highlight 
strengths and limitations of each study as well as their contributions to understanding 
disease burden. Cross-sectional designs are generally used to assess the frequency of 
an outcome in a given population at a particular point or period of time (Levin, 2006a). 
3.2 Mortality Data 
3.2.1 Study Summary and Critique – Publication 1 
Mortality data had been used in a number of countries to examine the 
frequency and distribution of Parkinson’s disease (PD), but had not been analysed in 
Canada until this study (Kurtzke & Goldberg, 1988). Publication 1 was the first, and so 
far only, Canadian study to look specifically at the geographic distribution of deaths 
attributed to PD using vital statistics records. The study found an uneven geographic 
distribution of PD in Canada, and suggested this supported aetiological hypotheses for 
PD centred on the role of environmental factors, primarily toxins. 
 Using publicly available data, from Statistics Canada, PD mortality rates were 
computed by year, sex, and province. The purpose of the study was to examine the 
geographic distribution of PD in Canada to see if there was any clustering as a means of 
generating potential aetiological hypotheses. Geographic clustering of disease may 
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imply that environmental factors play a role the aetiology of a given disease. However, 
it cannot not be concluded from descriptive analyses that this is, in fact, the case.  
 The geographic differences noted showed higher mortality rates for PD in the 
western provinces of Canada. These provinces also tend to have larger agricultural 
activity (Statistics Canada, 1999). These geographic differences were used to conclude 
that environmental factors likely played an aetiological role. Given the cross-sectional 
design, it was not possible to make inferences on the role of agricultural activity, but it 
was possible to develop hypotheses about the role of agricultural activity, and the 
possibility of chemical or other toxin exposures. Cross-sectional designs can be used to 
identify difference between groups, though are not well suited for understanding why 
the differences exist. 
Until this study, researchers had to rely on a limited number of studies 
conducted at different points in time, different locations, and often with different 
methods (Warren et al., 2005). This study provided a systematic assessment of the 
geographic distribution of PD. As a result, it was possible to generate hypotheses that 
supported other literature on aetiological hypotheses (Rajput, 1992). This 
demonstrated the value of using multiple approaches to improve our understanding of 
the burden of disease in general, and PD specifically.  
There was consistency with other studies conducted around that time pointing 
to higher prevalence among individuals living in more rural areas (Hertzman et al., 
1990; Kurtzke, 1977; Rajput, 1992). Consistency of findings across studies and 
locations, even if methods were different, increases the strength of the findings. In this 
case, consistency in finding higher disease prevalence in rural areas helped to refine 
aetiological hypotheses with a focus on what may be unique to the rural environment. 
There were limitations related to the study. These included a lack of 
information on birthplace, places of residence, age of disease onset, severity of illness, 
and that PD may not have been recorded as the underlying cause of death. The 
recording of the underlying cause of death may be biased. It is unknown what 
information the physician used, and it is often not possible to determine if the person 
 16 
died from or with a given disease. Studies have shown that among individuals with PD 
that have died, between 14.6% and 64% of descendants had PD listed on their death 
certificate (Benito-León et al., 2014; Paulson & Gill, 1995). Given the potential to miss a 
significant proportion of PD cases through the use of mortality data, it becomes 
difficult to make valid inference. Those with more severe presentations may be more 
likely to have PD listed on the death certificate.  
There may be other issues with mortality data that could compromise the 
interpretation of any findings. These include personal preference on where to die 
which could impact the assessment of geographic distribution; not all deaths result in 
an autopsy so important causes of death may go missed; and vital statistics agencies 
typically do not confirm the accuracy of the information submitted meaning coding 
errors could go undetected (Nielsen et al., 1991; Schnatter et al., 1990). These 
limitations, if not considered, could lead to misinterpreting evidence on the burden of 
not only PD, but also any condition. This could lead to the misallocation of services, and 
other resources.  
The limitations noted were offset by strengths such as: being population-wide 
coverage due to provincial laws requiring death certificates to be completed; 
uniformity of content and format set nationally; continuously collected over time; and 
the use of international standards for definitions and coding. Also, mortality data are 
accessible and well documented. Having systematically collected, population-based 
data, allowed for reliability of the results for assessing the geographic distribution. 
Also, mortality data represent one of the few sources of population level data collected 
internationally. This allows for comparisons that could not be done using other sources 
of information. 
 The study recommended future research focused on environmental factors in 
areas with higher mortality rates, and suggested that augmenting routinely collected 
data with other designs, like case control studies, would strengthen our understanding 
of potential risk factors for PD. It also recommended the use of hospitalisation data for 
estimating prevalence. The implications of these findings were that mortality data 
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could be used to assess geographic distribution of disease, and for hypothesis 
generation.  
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 3.3 Publication 1 
Svenson, L.W. (1990). Geographic distribution of deaths due to Parkinson’s disease in 
Canada: 1979 – 1986. Movement Disorders, 5, 322-324. 
Link: http://onlinelibrary.wiley.com/doi/10.1002/mds.870050412/abstract  
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3.4 Hospitalisation Data 
Publication 2 (Svenson, 1991) builds on the results from Publication 1 (Svenson, 
1990). In Publication 1, Svenson (1990) suggested that mortality data, as a measure of 
disease burden, could be improved through the examination of hospitalisation data. 
3.4.1 Study Summary and Critique – Publication 2 
 Publication 2  (Svenson, 1991) was a cross-sectional study that examined hospital 
separation (death of discharge of an inpatient) data from Statistics Canada to estimate 
the prevalence of Parkinson’s disease by Canadian province. The study found 
similarities as well as a few differences from the examination of PD mortality rates 
(Svenson, 1990).  
 A male preponderance for PD was noted, and this was consistent with other 
hospital-based studies as well as with the findings of Publication 1 (Kessler, 1972; 
Kurtzke & Murphy, 1990; Svenson, 1990). The geographic distribution of hospitalisation 
rates differed somewhat from that noted for mortality. Such differences may be the 
result of a number of factors such as coding practices, underlying severity of disease, 
differences in survival, or differences in likelihood of being hospitalised. The prevalence 
of disease was only one factor of many that would influence the likelihood of being 
hospitalised, and subsequently identified as a prevalent case. 
 The concept of using differing approaches, and data sources having different 
value and purpose was proposed in this paper. While there were differences between 
Publication 1 (Svenson, 1990) and Publication 2 (Svenson, 1991) related to the 
geographic distribution across Canadian provinces, both studies did note higher rates 
in provinces that tended to have higher levels of agricultural activity, or proportion of 
the population living in rural areas. This added further support to the view that PD 
resulted from exposure to environmental factors. 
While hospitalisation data are generally viewed as being accurate, there are a 
number of important limitations, some of which were highlighted in Publication 2 
(Svenson, 1991). There were two key limitations of the paper. First, the data were 
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based on the number of hospital separations, the discharge or death of an inpatient, 
and not the number of unique patients. Second, the analysis was based on location of 
hospitalisation, and not the province of residence of the patient. Because the data 
were based on separations and not unique individuals, there was the possibility of 
counting the same person multiple times resulting in an over estimation of prevalence. 
Hospitalisation data tends to bias results towards those most ill or in need of health 
services, as not everyone with PD will require hospitalisation (Butt et al., 2014).  
 While not known at the time of the study, more recent work has shown that 
the use of hospitalisation data may significantly under estimate the burden of PD (Butt 
et al., 2014; Danila et al., 2014). This supports the view that it is the more severe cases 
that are hospitalised. This would lead to a bias in understanding the burden of PD as 
the cases examined would over represent severe presentations, and under estimate 
less severe disease. This suggests that hospitalisation data should not be used for the 
estimation of measures like incidence and prevalence, but could potentially be used as 
a measure of burden among those with PD. Policy or resource allocation decisions for 
PD, based solely on hospitalisation data, could have unintended consequences as the 
allocation could be based on biased information. The bias would be to underestimate 
the prevalence of disease while over estimating the severity. Limiting decisions to the 
hospital setting may be prudent when only hospitalisation data are available. 
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3.5 Publication 2 
Svenson, L.W. (1991). Regional disparities in the annual prevalence rates of Parkinson’s 
disease in Canada. Neuroepidemiology, 10, 205-210. 
Link: https://www.karger.com/Article/Abstract/110271  
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3.6 Summary 
Both studies represented novel approaches, in 1990 and 1991, for trying to 
estimate the prevalence and burden of PD. While both studies helped to foster a better 
understanding of the epidemiology of PD, more recent research has shown that 
hospitalisation data may not be the best source for assessing prevalence (Butt et al., 
2014; Danila et al., 2014). Despite this, the fact that resources were being used meant 
the data had value for health service planning and resource allocation. It is the number 
of hospital separations, more than the number of people, which drives resource 
consumption. As such, a good understanding of hospital use can lead to not only 
efficient resource allocation, but also lead to work to define appropriate use, and 
identify optimum models of care.  
The use of either mortality or hospitalisation data must consider the primary 
purpose of the study. For example, mortality data provides a more accurate indication 
of survival or clustering of deaths temporally or geographically, while hospitalisation 
data will provide a better perspective on health system utilisation. Both may be used to 
develop hypotheses about aetiological factors, but caution is needed when used for 
health system planning, resource allocation, or determining health priorities. While 
hospitalisation data provides some indication of health system use, it does not allow 
one to know what proportion of individuals with PD end up hospitalised. It is possible 
that the more severe case are hospitalised, and this would result in a biased 
assessment of burden. 
Both studies represented an early part of the journey towards a better 
understanding of AHD and how it might be used to understand the burden of disease. 
The next chapter will examine how issues of data validity for estimation of incidence 
and prevalence can be addressed by using an algorithmic approach that combines 
multiple data sources.  
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Chapter 4: Case Definition Development to Improve Data Quality  
4.1 Introduction 
Population-based data on the incidence and prevalence of chronic diseases is 
important for understanding burden, setting priorities for resource allocation, and 
informing practice. Two sources of population-based data are generally available for 
this purpose – AHD and survey data. The accuracy of diagnosis has been considered a 
key limitation, or concern, cited with both surveys and AHD (Lix et al., 2008). For 
example, Wilchesky et al. (2004) assessed the validity of diagnostic information for 18 
conditions using medical claims data from Quebec, Canada and found the validity of 
codes varied by condition and that, in general, the specificity tended to be high, while 
sensitivity tended to be low. 
A case definition is a set of criteria used to establish a diagnosis (Last, 2007). 
Because AHD does not include details on the criteria used by a given physician, case 
definition algorithms can be created to minimize the risk of false positive detections, 
and to improve the accuracy of the data. A case definition algorithm selects records 
from one or more AHD sources based on a combination of visits with specific 
diagnostic or procedure codes over a fixed period of time (Lix et al., 2008). The source 
of the data determines the number of services one would need to have to qualify as a 
case. The purpose of the analysis determines if one chooses to err on the side of 
sensitivity (gives few false negatives, but may introduce false positives) or specificity 
(gives few false positives, but may introduce false negatives). To highlight 
considerations and contributions to the concept of developing case definitions as a 
means of improving the quality and utility of AHD, Publications 3 (Robertson et al., 
1998), 4 (Yiannkoulias et al., 2003) and 5 (Yiannakoulias et al., 2007) will be critiqued. 
4.2 Case Definition Development – An Example with Cerebral Palsy 
 Cerebral palsy (CP) is considered to be one of the most common motor 
disabilities of childhood. At the time of this study, there was debate in the literature 
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about the incidence and prevalence of this condition. The debate centred around views 
that the incidence of CP was changing as a result of changes in the percentage of 
preterm births (births prior to 37 weeks gestation), low birth weight births (weight less 
than 2,500 grams), and increasing survival among very low birth weight new-borns 
(weight less than 1,500 grams) (Pharoah et al., 1990; Stanley, 1994; Stanley & Blair, 
1991).  
4.2.1 Study Summary and Critique – Publication 3 
CP can be difficult to diagnose, often requiring multiple assessments over a 
period of time (Jutte et al., 2011). To address this problem, the current study used a 
unique approach by using multiple birth cohorts, and seven years of follow-up. This 
allowed for the accumulation of service events related to CP for each child. It was 
possible to look at the proportion of children receiving services for CP before and after 
their third birthday. Next, to avoid inclusion of children as CP cases that may have been 
misdiagnosed, services for conditions that would be considered for a differential 
diagnosis were also included in the analysis. This allowed for an exclusion of potential 
false positive cases leading to improved specificity. 
 For the case definition algorithm, a child was considered to have cerebral palsy if 
they met the following inclusion criteria: (1) the child received a medical service where 
a diagnostic code was provided for cerebral palsy when the child was three years of 
age or older or (2) any child with a cerebral palsy diagnosis prior to age three that had 
at least one additional service when they were three years of age or older. Following 
the inclusion criteria, the child was reclassified as being a false positive case if they had 
medical services with codes for other progressive neurological disorders. This approach 
was designed to err on the side of specificity ensuring there were few false positive 
cases included in the estimation of incidence. 
 This study demonstrated that AHD could be used to develop retrospective 
cohorts using inclusion and exclusion criteria for case identification. A closed cohort 
approach was used which fixes the members of the cohort so that no new members 
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are added. Existing members can only exit by moving from the province or dying. This 
limited the potential for confounding factors to influence the findings.  
 Within the province of Alberta, this was the first population-based study of CP. 
It augmented previous work that was only focused on new-borns weighing less than 
1,250 grams at birth by providing prevalence estimates for the entire range of birth 
weights. A better understanding of the impact of birth weight and CP can help with 
estimations of special needs assistance, and other services for children with CP as well 
as for their caregivers. It also showed that there was no difference in prevalence across 
three birth cohorts. Differences in prevalence across birth cohorts could indicate issues 
with the prevalence of underlying risk factors. The estimates derived in the study were 
consistent with those found by others (Murphy et al., 1993; Stanley, 1994; Stanley & 
Blair, 1991). 
 There were also limitations that require consideration. First, no validation was 
done on the diagnostic codes included in the study. While an algorithmic approach was 
used to improve specificity, the study would have benefitted from examining charts for 
a sample of the children. This would have provided additional evidence on the accuracy 
of the approach used. While the lack of validation does not mean the data are invalid, 
the assessment of validity would work to strengthen the credibility of the findings. 
Case capture was based on utilisation of health services. Variations in how 
services were accessed, as well as where, may limit the diagnostic information 
available for assessing inclusion and exclusion criteria.  Assuming the approach ensured 
all cases classified as having CP were correct, it is likely that this increased the number 
of false-negative cases. The application of a case definition algorithm would err on the 
side of specificity. This would work to underestimate the incidence and prevalence of 
the condition. This could lead to poor decisions on the number and type of health 
professionals needed to meet the demand of newly diagnosed cases. Also, it may 
negatively impact decisions on the placement of specialty services, particularly by 
geographic location, that could result in availability and accessibility issues for 
managing cases.   
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4.2.4 Publication 3 
Robertson, C.M.T., Svenson, L.W., & Joffres, M.R. (1998). Prevalence of cerebral palsy 
in Alberta. Canadian Journal of Neurological Sciences, 25, 117-122. 
Link: 
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=950
4712&fulltextType=RA&fileId=S0317167100033710  
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4.3 Case Definition Development – Geographic Considerations 
 Cerebrovascular disease is the third leading cause of death in Canada making it 
an important contributor to disease burden, for the individual, their families, and the 
health care system. AHD have been recognised as a cost-effective, timely, and 
generalisable resource for the surveillance of cerebrovascular disease (Tirschwell & 
Longstreth, 2002). However, it has been noted that the accuracy of diagnostic codes 
for cerebrovascular disease varies across studies (Reker et al., 2001). There appeared 
to be uncertainty in the quality of the coding of a cerebrovascular diagnosis as well as 
variability in coding practices across different geographic areas (Liu et al., 1999). These 
factors make it difficult to understand if temporal or geographical variability is true or 
related to issues of misclassification or coding practices. The purpose of this study was 
to describe and evaluate geographic differences in cerebrovascular disease.  
4.3.1 Study Summary and Critique – Publication 4 
 Given the above limitations, there was a need to understand the issue in greater 
detail. To do so, inpatient and outpatient data were linked from all hospitals in Alberta 
for patients receiving one or more cerebrovascular diagnoses during the 1999-2000 
fiscal year (April to March).  
 The study noted important differences in how urban and rural hospitals coded 
individual cases. Rural facilities tended to use less specific coding for cerebrovascular 
disease than did urban facilities. However, for rural patients that were transferred to 
an urban centre, when they returned to the rural facility they retained the more 
specific coding of the urban facility on the administrative health record.  
 The approach and results demonstrated that assessing the burden of 
cerebrovascular disease using AHD required a large-scale person-oriented approach. 
The differences between urban and rural facilities was an important contribution as it 
demonstrated that access to both specialists and diagnostic imaging appeared to result 
in more specific as well as a broader range of cerebrovascular disease coding. Our 
findings showed the value to a person-oriented approach, particularly when trying to 
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assess geographic differences in the distribution of disease. By following individual 
patients, it was possible to attach a more specific, and potentially more accurate 
diagnosis, to the patient for those that travelled between rural and urban facilities. The 
study also provided considerations for the interpretation of geographic differences, 
particularly when there may be factors that may bias results, such as the availability or 
access to specialists, and specialized equipment. 
 The type of cerebrovascular event (ischaemic, haemorrhagic) may result in 
different approaches to managing the patient, and understanding their prognosis. Also, 
the geographic distribution of stroke type could help to identify potential risk factors 
that are unique to a geographic area. The frequency and type also provide information 
for service level planning, resource allocation, and staff training. The lack of specificity 
of coding in rural facilities suggests a need to better connect them to specialists within 
urban centres as a means of triaging, assessing risk, and need for medical transport. 
From a research perspective, our results demonstrate the need for a person-oriented 
approach to analysing data, and that results may be influenced by practice patterns. 
The study highlighted the importance of understanding not just the data source, but 
also the activities in the health system that might impact the precision of coding, and 
subsequent interpretations of the data. 
While the study was well designed for its purpose, there were limitations that 
could impact the interpretation of findings. While there appeared to be coding practice 
differences that may be attributable to access to diagnostic imaging technology or 
specialists, the study did not look at the availability of either. The diagnostic codes 
provided were not validated, but assumed to be an accurate reflection of the 
information on the patient chart. It was also not possible to assess patient preferences 
in the type of facility they would visit or where the patient was at the time of the event 
that resulted in needing to be hospitalised. Despite these limitations, the paper 
demonstrated the importance of understanding the context in which the data were 
collected as it aids with interpretation, and use of the findings. 
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4.3.4 Publication 4 
Yiannakoulias, N., Svenson, L.W., Hill, M.D., Schopflocher, D.P., James, R.C., Wielgosz, 
A.T., & Noseworthy, T.W. (2003). Regional comparisons of inpatient and 
outpatient patterns of cerebrovascular disease diagnosis in the province of 
Alberta. Chronic Diseases in Canada, 24, 9-16. 
Link: http://publications.gc.ca/collections/collection_2009/aspc-phac/H12-27-24-
1E.pdf  
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4.4 Case Definition Development – Impact of Changes to Patient Residence  
Many chronic conditions vary geographically, and this may be used to generate 
hypotheses about aetiological agents or to facilitate the planning of health services. 
Unfortunately, a number of factors can complicate the interpretation of geographic 
clustering. These include, latency periods from exposure(s) to disease onset, small 
sample size, physician practice pattern variations, availability of health services, and 
health service seeking behaviour of individuals with a chronic condition. Boyle (2004) 
has speculated that those with a chronic condition may be disproportionately more 
likely to move following the onset of their condition. If this were true, then geographic 
differences in disease prevalence will not represent variations in in situ risk, but rather 
systematic changes in residence. 
 The issue may negatively impact public health policy and programs developed 
in light of a perceived risk to a given geographic area. An inaccurate understanding of 
the geographic distribution could lead to less than optimal allocation of resources, 
whether they be funding, personnel, or physical infrastructure. Also, some areas may 
be viewed as better or worse for providing services to chronically ill individuals, and 
this has implications for resource planning, and allocation, as well as measures of 
equity in healthcare.  
4.4.1 Study Summary and Critique – Publication 5 
To better understand the relationship between the onset of a chronic illness 
and the probability of a change in residence, Publication 5 used administrative health 
data to set up a longitudinal study to quantify changes in residence among individuals 
newly diagnosed with either multiple sclerosis (MS) or Parkinson’s disease (PD), and 
compared this to age- and sex-matched controls. In addition to quantifying the 
proportion of individuals changing residence, we also estimated the impact this change 
in residence would have on geographically based prevalence estimates. 
To examine changes in residence between 1994 and 2004, data were extracted 
for the period 1983 to 2005. A case definition algorithm was used to reduce the risk of 
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including false positive cases. The run-in period included all data between 1983 and 
1993 was a means of excluding any individuals that may have had a history of MS or PD 
prior to the study period. Cases were matched on sex, age (± 5 years), socioeconomic 
status, and municipality of residence. Changes in residence were then identified 
through the Alberta Health Care Insurance Plan (AHCIP) population registry. 
Individuals with MS or PD had different mobility characteristics than did the 
control group. Newly diagnosed cases of MS or PD were more likely to move following 
their diagnosis, but this was primarily within the same municipality. There was a 
tendency for both MS and PD groups to move to or between the two largest urban 
centres in the province, and both groups were significantly less likely to move out of 
province relative to their respective controls. While there were changes in residence 
following a diagnosis of MS or PD, the impact of the mobility was assessed to be minor 
when developing regionally based prevalence estimates. 
Using a longitudinal design and linking data from multiple AHD sources, it was 
possible to compare changes in residence among a large number of individuals with 
two chronic conditions, and compare them with the general population. The design 
included the concept of a run-in period to increase the likelihood that those identified 
were newly diagnosed cases of either MS or PD. Linkage to a population-based health 
insurance registry that tracks changes in residence with dates on when changes were 
made provides a valuable tool for assessing residential changes. Having the estimated 
incidence date and dates of any moves allowed for changes post diagnosis to be 
tracked. Being able to assess address changes in this manner would appear to be 
superior to asking individuals for their address histories, which would introduce issues 
of recall bias. This would be particularly problematic for PD where cases are generally 
older. 
Limitations of the study were primarily related to the nature of AHD in general. 
It was not possible to assess the true incident date for cases. We could only estimate 
this based on contacts with the health care system. Individuals who had either 
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condition, but who were not yet diagnosed, might have been more or less inclined to 
move, but we would not be able to assess this or determine if it had an impact on the 
migration patterns. This could result in an underestimation of any changes in 
residency. 
Even with the extended run-in period, it is possible that some individuals were 
diagnosed with either condition but did not have any services with the specific 
diagnosis leading up to the study period. Thus, any diagnosis received during the study 
period would be viewed as incident, when they were prevalent. This also applies to any 
individual receiving a diagnosis from a health care provider outside of the province. 
This information would not be available within AHD. The study only examined the first 
change in residence following a diagnosis, and not all subsequent changes were 
captured. Finally, postal codes were used for geo-referencing, and these are not 
equally precise across the province. In rural areas, a single postal code may cover a 
large area including multiple communities. If the communities differ significantly from 
each other on attributes related to the likelihood of moving, then the results may be 
biased towards a null finding even if one or more of the communities had members 
more likely to move. 
An understanding of migration patterns helps to improve aetiological 
hypotheses. If individuals with either disease have been resident in an area for their 
whole life, or a significant proportion of their lives, then one could look to 
environmental factors unique to, or in high concentrations, within that geographic 
area. Also, it helps to quantify the likelihood that patients and their families might 
move following diagnosis. Understanding migration patterns helps to inform decisions 
about the allocation of resources, such as health professionals and clinics. However, 
not knowing why the person moved, it is difficult to fully understand the implications 
from a health policy development perspective or to fully address patients’ service 
needs.   
 33 
4.4.4 Publication 5 
Yiannakoulias, N., Schopflocher, D.P., Warren, S.A., & Svenson, L.W. (2007). 
Parkinson’s disease, multiple sclerosis and changes in residence in Alberta. 
Canadian Journal of Neurological Sciences, 34, 343-348. 
Link: http://dx.doi.org/10.1017/S0317167100006806  
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4.5 Summary 
While creating case definition algorithms using multiple services over a 
specified period of time appears to be a valuable approach, there are other 
considerations that needed to be assessed. Diagnostic coding practices change across 
geographic area, with urban centres more likely to use both specific codes as well as a 
broader array of codes. This can impact our understanding of the distribution of 
cerebrovascular disease type (Yiannakoulias et al., 2003). While this issue may not 
impact estimations of the burden of cerebrovascular disease, it does need to be 
considered when interpreting any study that included urban and rural facilities with 
differing access to diagnostic technology and medical specialists. Region-to-region 
differences need to be understood to ensure appropriate interpretation of findings. 
While the example used cerebrovascular disease, the findings would generalise to any 
chronic condition that requires specialised tools for confirming the diagnosis. 
Understanding if people move closer to specialty services can play a role in 
understanding current and future health service needs. This chapter demonstrated 
that migration does occur following a diagnosis of a chronic condition (i.e. MS, PD), but 
does not occur at a level that would impact the geographic estimation of prevalence, 
nor negatively impact the development of aetiological hypotheses, or inform resource 
planning and allocation (Yiannakoulias et al., 2007).  
The three publications demonstrated that a thorough understanding of AHD 
and the application of novel approaches could lead to better understanding the burden 
of disease. The next chapter will explore the value of longitudinal designs for improving 
our understanding of disease burden and risk. 
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Chapter 5: Using Administrative Health Data for Longitudinal Designs 
5.1 Introduction 
 Cohort designs, a form of observational study, are used to look at associations 
that may be difficult, or unethical, to assess via other means (Patten, 2015). The term 
cohort is used to describe any group that has common features, and is typically divided 
into either prospective or retrospective. Cohort studies typically start with a group free 
from an outcome, and follow them to forward to determine which members develop 
the outcome of interest as a way of clarifying the temporal relationship between an 
exposure and outcome (Patten, 2015). 
 While cohort designs are well suited to determining temporality and relative 
risk measures, among others, they have issues. First, they tend to be expensive to 
conduct, and may require lengthy follow-up periods. As the follow-up period increases, 
issues of attrition may introduce bias. Also, prospective studies are typically inefficient 
for studying rare conditions given the large cohort size needed. Given the cost, 
logistics, and complexity associated with the development of prospective cohort 
studies, AHD is an attractive alternative. While AHD may not have in-depth details on 
each case that comes from primary data collection, they can overcome issues of cost, 
timeliness, and attrition. This chapter will examine and critique Publication 6 
(Yiannakoulias et al., 2004) that used a longitudinal design to assess patient to 
physician and physician to patient disease transmission. 
5.2 Study Summary and Critique – Publication 6 
This retrospective longitudinal study was initiated, in part, to provide evidence 
for the development of a pandemic influenza response plan for the province of Alberta. 
One of the assumptions embedded in many pandemic plans was that healthcare 
workers would have a higher probability of being infected as a result of the number of 
patients they would see that had influenza (Wilson et al., 2005). The current pandemic 
response plan for the province of Alberta includes a section that speaks to the 
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increased demand on healthcare workers as a result of a pandemic. It recognizes that 
the demand for healthcare services will be higher due to the number of infected 
individuals, as well as likely reductions in health workforce resulting from healthcare 
worker illness, need to care for family members, or fear of becoming ill (Government of 
Alberta, 2014).  
Without specific information on the direct impact of a pandemic on healthcare 
worker illness, non-pandemic studies can be used to provide a lower bound estimate of 
the impact of a pandemic on the health workforce. Prior to our study, research 
predicted that approximately one quarter of healthcare workers could be infected, and 
many would choose to continue working, even while infectious (Odelin et al., 1993; 
Wilde et al., 1999). 
 Using a longitudinal design, Publication 6 (Yiannakoulias et al., 2004) examined 
two key questions. First, does the probability of a physician being infected vary with 
the number of patients seen with influenza-like illness (i.e. influenza, pneumonia, 
bronchitis)? Second, does a physician, who had been treated for an influenza-like 
illness, infect his/her patients? To answer these questions, we developed a unique 
approach to the use of administrative data by placing the physician in two roles – one 
as a healthcare provider, and second as a patient. 
 To ensure we could limit the data as much as possible to answering the second 
question about to the physician-patient interaction, a matched design was used. The 
study physicians were those who had received an influenza-like illness (ILI) diagnosis, 
and were then matched to physicians who did not have an ILI diagnosis. Matching was 
done on age (± 5 years), gender, residence location, medical specialty, and the number 
of claims submitted in a year. 
 The study found that the number of patients, with influenza-like illness, seen 
increased the probability a physician would be diagnosed with influenza-like illness. 
When examining the odds of a physician infecting a patient, we found no statistically 
significant increase in the number of patients developing ILI following a visit with an 
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infected physician. The study showed the risk was primarily in the direction of patient 
to physician. This supported the need to ensure high vaccination rates among 
physicians as well as the use of other preventative measures such as good hand 
hygiene practices (Aiello et al., 2010). This is important given the recent study by 
Aoyagi et al. (2015) showing healthcare workers indicated a moderately high 
willingness to work during influenza pandemics, and that this was driven, in part, by 
their perceptions of risk. 
 A number of strengths can be identified with the approach used. There was no 
need for contact with physicians, or their patients, reducing recall bias, and the chance 
of low participation rates. Physicians were placed in two roles – one as a health care 
provider, and second as a patient. Having access to data on health system encounters 
in both roles allowed us to quantify the number of patients seen, and the diagnoses 
provided leading up to the physician being diagnosed themselves. Once the physician 
had been diagnosed, it was possible to determine if the physician had subsequently 
transmitted disease to future patients. By having the dates of all services, it was 
possible to look at this from a temporal perspective. The number of patients seen 
could be quantified as a risk factor as well as the subsequent risk for patients seeing an 
ill physician. The use of a control group helped to reduce the potential for confounding. 
 A number of limitations do need to be highlighted. First, the purpose was to 
provide empirical evidence on the risk of a physician treating a person with ILI 
becoming ill. This was done using data during a seasonal and not pandemic situation. 
Pandemic influenza strains tend to be more virulent, and spread more rapidly than do 
seasonal strains (Kasowski, et al., 2011). As such, the estimations of risk were likely 
underestimates. The diagnosis provided for both the physician and the patients could 
not be confirmed. It was not possible to assess how many of the cases were laboratory 
confirmed, or the criteria used if the diagnosis was based on a clinical assessment. 
 The data were based on when the person sought medical care making it difficult 
to fully assess the period of communicability. If a person presented late in the disease 
course, he or she might no longer be infectious, and this would lead to an 
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underestimation of risk. It is not known if physicians seek medical care in ways that are 
consistent with the general population. It is possible for physicians to self-diagnose, or 
to be seen by a colleague in the same practice with no record created. Approximations 
of patient to physician and physician to patient transmission would be underestimates. 
5.5 Summary 
 The publication showed a novel application of a longitudinal design based on 
AHD. It contributed new knowledge on the risk of influenza-like illness transmission 
between patients and physicians, and from physicians to patients. While it was clear 
that the effects were underestimates, they still provide empirical evidence that 
transmission does occur. The more patients with ILI a physician sees, the more likely 
the physician will become ill him or herself. It does suggest that in a pandemic 
situation, physicians are at an increased risk of being infected, but if they choose to 
practice their future patients will not have a significant increase in disease transmission 
from their physician. 
 The study followed a cohort of physicians and their patients at a population level. 
It would have been difficult to perform this type of study using primary data collection 
approaches. A large prospective cohort would be required with data collection carried 
out across numerous family practices. The sample size that would have been required 
would have made such a study challenging and resource intensive. While the results 
have applicability for pandemic influenza planning as well as understanding physician 
risk in non-pandemic situations, the approach could be generalised to other situations. 
Longitudinal designs provide strong evidence, and can be conducted readily using AHD.  
 The next chapter will look to the use of AHD for estimating the prevalence of a 
rare health event, and also look at the value of AHD for determining the burden of 
comorbidities. 
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5.6 Publication 6 
Yiannakoulias, N., Russell, M.L., Svenson, L.W., & Schopflocher, D.P. (2004). Doctors, 
patients and influenza-like illness: clinicians or patients at risk? Public Health, 
118, 527-531. 
Link: http://dx.doi.org/10.1016/j.puhe.2004.02.005  
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Chapter 6: Assessing Rare Events and Comorbidities  
6.1 Introduction 
The strength of AHD becomes apparent when trying to quantify the prevalence 
or incidence of rare events, as primary data collection is often cost-prohibitive. There is 
no single accepted definition of rare disease available. However, the European 
Commission and the Canadian Organization for Rare Disorders both define a rare 
disease as one with a prevalence that is less than 5 in 10,000 (Canadian Organization 
for Rare Disorders, 2015; European Commission, n.d.). Rare conditions represent 
unique challenges. Population-based surveys that are large enough to ensure reliable 
estimates are often cost prohibitive and logistically difficult. Accessing data from 
disease specific societies or charities can be challenging, and result in biased samples. 
Given these challenges, population-based AHD may provide a viable solution to 
determining disease incidence and prevalence.  
 Multiple measures are available for assessing the burden of illness (for example 
incidence, prevalence, mortality, case fatality) (Patten, 2015). The complexity of an 
illness is increased with the number of comorbidities of the patient, and this accounts 
for a significant amount of the variation in health care costs across patients (Engström 
et al., 2006). Using Publications 7 (Svenson et al., 1999) and 8 (Patten et al., 2007) as 
examples, this chapter will highlight the value of AHD for assessing rare events and for 
identifying comorbidities. 
6.2 Assessing Rare Events – An Example with Motor Neurone Disease 
6.2.1 Study Summary and Critique – Publication 7 
 Motor neurone disease (MND) refers to a group of rare progressive neurological 
disorders that attack motor neurones that control voluntary muscle movement, with 
amyotrophic lateral sclerosis (ALS) being the most common (Adams et al., 1997). MND 
has a median survival of two to three years following diagnosis (Lee et al., 1995).  
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 At the time of our study, there had only been two Canadian studies that assessed 
the epidemiology of MND. The first study was conducted by Hudson et al. (1986) and 
focused on MND in southwest Ontario between 1978 and 1982. The second study 
examined incidence of MND in the province of Nova Scotia (Murray et al., 1974). Both 
studies relied on a review of records from either a specialty clinic or from a single 
hospital thus limiting the generalisability of their findings. 
 We used a cross-sectional study design to estimate the prevalence of MND. 
Given that most studies on the epidemiology of MND were either community or clinic-
based with limited ability to generalise to the population level, we felt that AHD may 
be able to provide a valuable contribution.  
 While it is not always possible to confirm the diagnostic information available 
through administrative health data, it was possible to examine both the location of any 
given service as well as the specialty of the physician. We found that 84% of the cases 
identified had been diagnosed by a neurologist, neurosurgeon, or internal medicine 
specialist, and that 66% were seen at one of the two neuromuscular clinics operating in 
Alberta (Svenson et al., 1999). While access to specialists and specialty clinics may vary 
by jurisdiction, we were able to show that even in a situation where there are universal 
publicly funded health services available, approximately one third of patients were not 
seen by either a specialist or specialty clinic. This suggested that there might be issues 
of completeness of case ascertainment if one only uses specialty clinics as a source for 
estimating the incidence or prevalence of MND. The study demonstrated that 
administrative health data appeared to be a reliable means of studying the 
epidemiology of this rare condition. 
 Limitations to the study need to be acknowledged. First, the assessment of 
prevalence is dependent on individuals with MND both seeking medical services and 
receiving a diagnosis for MND. Given the rapidly progressive nature of MND, it was 
assumed that most, if not all, of the cases would have been identified. There was no 
validation of the diagnostic information available, or how physicians assessed cases, 
and determined the diagnosis. However, close to three quarters of the cases had been 
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seen by a medical specialist, and close to two thirds received their diagnosis from a 
neuromuscular disease specialty clinic. The third potential limitation was that of 
immigration. For any individual moving into the province that was diagnosed outside of 
the province then the initial diagnosis information would not be available. However, 
the progressive nature of the disorder would work towards limiting migration, and 
given this was an assessment of prevalence, it can be assumed that they would 
eventually receive a code for MND on one or more of their contacts with the health 
care system. Those diagnosed outside the province could impact measures like 
incidence, but once identified in Alberta, they would be included as a prevalent case. 
Any delays in reporting would mean under estimating prevalence. 
 Understanding the prevalence of a condition allows for a better understanding of 
the health and health services needs of a population. With rare conditions, it is 
important to understand where cases reside to ensure appropriate services can be 
provided, whether they are institution or home-based. The use of AHD for this purpose 
provided a less biased, and more complete understanding of the number and 
distribution of cases, than the use of other sources (for example specialty clinic, not-
for-profit society). Changes in the prevalence of MND where the survival is short may 
also inform the effectiveness of interventions on survival.  
 The value of using of AHD for determining the prevalence of a rare condition is 
evident. First, identification of cases was done using a low cost and non-intrusive 
approach. There was no need to contact individuals, their care providers, specialty 
clinics, or hospitals directly. Routine AHD was generated through normal interactions 
with the health care system. Second, it was possible to assign cases geographically to 
their residence location regardless of where they sought or received care. This allowed 
for a more accurate representation of the geographic distribution of disease. Third, the 
health care system in Alberta is publicly funded and universally available so there were 
no financial impediments to accessing care, which works to increase the likelihood of 
identifying cases. 
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6.2.4 Publication 7 
Svenson, L.W., Cwik, V.A., & Martin, W.R.W. (1999). The prevalence of motor neurone 
disease in the province of Alberta. Canadian Journal of Neurological Sciences, 26, 
119-122. 
Link: http://www.ncbi.nlm.nih.gov/pubmed/10352871  
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6.3 Assessing Comorbidities –Motor Neurone Disease and Affective Disorders 
6.3.1 Study Summary and Critique – Publication 8 
A number of studies suggested that there might be an increased prevalence of 
affective disorders among individuals diagnosed with motor neurone disease (MND) 
(Hogg, et al., 1994; Jau-Shin et al., 2003; Kilani et al., 2004; Moore et al., 1998). 
However, these studies generated conflicting results, primarily due to small sample 
sizes. None of these studies were population-based in nature so lacked the required 
statistical power to determine if MND was associated with an increased risk of an 
affective disorder. 
Publication 8 (Patten et al., 2007) was a cross-sectional study that examined the 
prevalence of affective disorders among individuals with MND. At the time the study 
was published, it was the first to use population-based administrative data to examine 
affective disorders among people with MND. Up to this point, studies had to rely on 
disease registries, disease-specific non-government organisations, specialty clinics, or 
hospital based ascertainment. Each of these options may be biased in how cases were 
ascertained leading to skewed estimations of prevalence and overall burden.  
Data were extracted for six affective disorders for the entire population. Next, 
individuals with MND were identified allowing for estimates of affective disorder 
prevalence for those with and without MND. It also provided the necessary statistical 
power to provide stable estimates. Our analysis was able to demonstrate the existence 
of an association between affective disorders and MND.  
 Relative to other studies at the time, a key strength of this study was being 
population-based. This limited the potential for selection bias. It also ensured there 
was sufficient statistical power to assess the association between MND and affective 
disorders, a problem other studies had (Hogg, et al., 1994; Jau-Shin et al., 2003; Kilani 
et al., 2004; Moore et al., 1998). The limited sample sizes in previous studies may be 
the reason for the inconsistent findings, resulting from an increased risk of a type II 
statistical error.  
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The population-based nature of AHD, combined with the high health care needs 
of MND patients worked to reduce issues other studies had related to selection bias or 
limited statistical power. Aside from demonstrating the value of administrative data for 
assessing comorbidities, particularly for rare conditions, the study also contributed 
meaningful results for clinicians. For example, we were able to show that the odds of 
being diagnosed with an affective disorder were greatest in the first year of illness, and 
then decreased with illness duration. We postulated that this might represent a 
process of adjustment whereby the psychological impact of MND decreases with time, 
and recommended additional studies examining the mental health care needs of 
individuals living with MND. 
 While this study advanced our understanding of the association between MND 
and affective disorders, there were limitations. MND is a group of neuromuscular 
conditions and each has a different progression. This introduced heterogeneity in the 
cases that may have had differences in survival probabilities, and this could have 
explained the weakening of the association between MND and affective disorders with 
increasing duration of illness. AHD is not well suited to clarify issues of this nature. The 
accuracy of the affective disorder diagnosis could not be confirmed through AHD. Also, 
it was not possible to differentiate major depressive episodes from bipolar disorders. 
This means the categorization of affective disorders includes a wide range of severity.  
Detailed clinical notes were not reviewed. A review would have helped to better 
understand the treatment the patient received and validate the findings. 
 The design allowed for a direct comparison with the entire population of the 
province, not something done in the other studies. It showed that MND increases the 
risk of being diagnosed with an affective disorder that is above what is seen in the 
general population. For clinicians, this provides an opportunity for earlier intervention, 
and to take into account the mental state of the patient when treating all aspects of 
MND. The presence of physician diagnosed affective disorders, even if inaccurate, 
represents a clinically meaningful event.   
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6.2.4 Publication 8 
Patten, S.B., Svenson, L.W., White, C.M., Khaled, S.M., & Metz, L.M. (2007). Affective 
disorders in motor neuron disease: a population-based study. 
Neuroepidemiology, 28, 1-7. 
Link: https://www.karger.com/Article/Abstract/97849  
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6.3 Summary 
Using publications 7 (Svenson et al., 1999) and 8 (Patten et al., 2007) as 
examples, this chapter demonstrated the value of AHD for assessing the prevalence of 
rare events and for identifying the presence of comorbidities. When studying rare 
conditions, primary data collection techniques may lead to small sample sizes that limit 
statistical power or to biased samples that limit the ability to generalise the findings. In 
addition, the logistics and resources to find study subjects can be substantial. While 
there are limitations to the use of AHD, its population-based nature makes it a good 
starting point for descriptive epidemiological studies of rare conditions. 
 AHD allowed quantification of comorbidities associated conditions that have an 
impact on health system utilisation, costs, and complexity for managing the patient. 
Therefore, health care providers to be better prepared when consulting with patients, 
developing treatment and management plans, and allocating resources.  
 A better understanding of comorbidities helps to inform practice. The more 
clinicians know about all health needs of their patients, the better they can develop 
management plans. It is generally known that affective disorders impact on how a 
patient perceives their health, impacts their quality of life, and can negatively affect 
patient compliance with medication use and other strategies aimed at improving their 
health status (Cameron et al., 2014). The high rate of affective disorders, particularly in 
the year of initial diagnosis, suggests that clinicians must factor in mental health early 
in the management of this condition. 
In addition, it provides researchers with the means of examining associations in a 
way that can inform resource allocations and inform front line practice. They also 
generate important hypotheses that could be addressed through primary data 
collection means, which would add the depth of understanding that is not present with 
AHD alone. AHD can, therefore, be used to drive research priorities and a better 
understanding for improving practice, and training of health professionals. The next 
chapter will explore the role of AHD for assessing risk and outcomes.  
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Chapter 7: Assessing Outcomes and Risk with Administrative Health Data 
7.1 Introduction 
There is general agreement that systematic reviews and meta-analyses of 
randomised control trials (RCTs) are trustworthy forms of evidence, followed by: RCTs, 
cohort studies, case-control studies, cross-sectional surveys, case reports, and finally 
perspectives or expert opinion (Evans, 2003). AHD represents an opportunity to 
evaluate the implementation of new treatments at a population level, and add 
information an RCT would have been underpowered to detect. This allows for a better 
understanding that may help explain gaps between the efficacy in an RCT and 
effectiveness in the community. 
AHD allows for a population-level assessment of the impact of actions taken 
(for example policies, guidelines, and new interventions) by examining their use in the 
‘real-world’. For example, RCTs designed for vaccines generally include assessment of 
adverse events, but may be underpowered to detect rare, yet important adverse 
events. The linkage of multiple AHD sources, using a cohort design, can be done to 
quantify adverse events following the introduction of a new intervention, and thereby 
add information not available through an RCT. A population-based approach reduces 
issues with power to detect as well as the opportunity to control for a number of 
health conditions that may independently increase a particular adverse event 
(MacDonald et al., 2014). This will be explored in Publication 11. 
Another aspect of risk that will be explored is related to the role of 
environmental and genetic factors in the onset of disease. Publication 9 will describe 
how the linkage of multiple AHD sources, using an ecological study design, was done to 
explore the role of parental ancestry and MS (Warren et al., 1996). The findings will be 
compared with Publication 10 that looked specifically at MS prevalence among First 
Nations people in Alberta, Canada, highlighting how using different approaches can 
lead to a better understand the epidemiology of MS (Svenson et al., 2007). 
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7.2 An Example with Parental Ancestry and Multiple Sclerosis – Publication 9 
7.2.1 Study Summary and Critique – Publication 9 
 The uneven geographic distribution of multiple sclerosis (MS) has been well 
established for decades and this knowledge has been used to create hypotheses 
suggesting a role for viral and/or environmental factors, along with genetic 
susceptibility, in the development of MS (Kurtzke, 1977). It had also been noted that 
MS appeared to be more common not only within certain geographic areas, but also 
among certain ethnic groups (Bullman & Ebers, 1992; Davenport, 1993; Page et al., 
1993). Page et al. (1993) looked at the prevalence of MS across US states, and noted an 
association between MS and European ancestry, particularly those of Scandinavian 
descent. However, the authors stated they could not rule out the possibility of an 
ecological fallacy. 
 Publication 9 (Warren et al., 1996) was designed to examine the relationship 
between the geographic distribution of MS in the province of Alberta, Canada and self-
reported parental ancestry, and to compare these findings with those from a case 
control study. This study had two embedded designs. The first was an ecological 
design, and the second was a case-control design.  
 The addition of the case control component was done to assess the potential for 
an ecological fallacy that could be present when using an ecological design. Prevalence 
rates were age-standardized, using the direct method (Fleiss, 1981) to remove any 
influence of differing age-distributions across the census divisions. The Canadian 
census data was then accessed and aggregated by sex, self-reported ancestry, and 
census division. This allowed for a comparison between an ecological study, and one 
based on primary data collection. 
 The ecological component of the study found results that were consistent with 
other research (Bulman & Ebers, 1992; Page et al., 1993) with Scandinavian ancestry 
appearing to be associated with a higher prevalence of MS for males. A negative 
correlation between MS prevalence and Aboriginal ancestry was noted. 
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 The association found with the ecological component was strengthened by the 
inclusion of a case control study design. The combination of two designs into a single 
study made it possible to determine if an ecological fallacy may have been present in 
other studies. The use of AHD essentially added statistical power to the case-control 
component. It was possible that the case definition used for the ecological component 
may have introduced false positives, which would work to decrease the magnitude of 
the association. The ecological component suggested that Aboriginal ancestry was 
associated with lower prevalence of MS. AHD provided population-level data while the 
case-control study provided more depth and rich data to the process. It was possible to 
show that some of the variation in MS prevalence is attributed to ethnicity, and not 
simply geographic location. 
 A few key limitations need to be highlighted. The capture of MS cases was done 
based on a patient having at least health service for MS within a five-year period. This 
could have increased the number of false positive cases included in the analysis. The 
impact of this on the findings cannot be determined, but it is possible that association 
between ethnic origin and MS could be obscured. The case-control study was relatively 
small to provide a reliable estimate of the role of ethnic origin. As a result, countries of 
origin needed to be grouped. This introduced heterogeneity to the case group that 
would work to limit finding relationships between MS prevalence and ethnicity.  
 Despite the limitations, the study demonstrated that MS prevalence varies by 
ethnicity. This supports the role of genetics in the risk of MS, but does not allow an 
assessment of the nature of the genetic role. However, this adds support to justify 
additional aetiological research that includes a genetic component. 
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7.2.4 Publication 9 
Warren, S., Svenson, L., Woodhead, S., & Warren, K.G. (1996). Parental ancestry and 
risk of multiple sclerosis in Alberta, Canada. Neuroepidemiology, 15, 1-9. 
Link: https://www.karger.com/Article/Abstract/109883  
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7.3 First Nations and Multiple Sclerosis – Publication 10 
7.3.1 Study Summary and Critique – Publication 10 
 In Publication 9, Warren et al. (1996) looked at parental ancestry and MS 
prevalence, and noted that geographic areas with a higher proportion of people of 
Aboriginal descent had lower prevalence rates of MS. Two Canadian studies had found 
MS prevalence to be lower among Aboriginal populations, but neither were 
population-based studies (Hader et al., 1985; Mirsattari et al., 2001). In Canada, there 
are three recognized Aboriginal populations – First Nations, Métis, and Inuit (Todd et 
al., 2001).  
 Publication 10 (Svenson et al., 2007) used a cross-sectional study design to assess 
the prevalence of MS among the First Nations population. The study found the 
prevalence of MS among First Nations people was approximately one third of that of 
the general population. However, when compared to international studies, the 
prevalence would still be considered high (Lauer, 1994). This supported a view that MS 
resulted from a complex interaction between genetically predisposed people and some 
factor, or factors, in the environment (Sadovnick & Ebers, 1993). It was the first 
population-based study in Canada to systematically look at the prevalence among an 
Aboriginal population. As such it provided a baseline or reference point from which 
other studies could compare. 
 A better understanding of the prevalence of MS in Aboriginal populations helps 
to understand where resources need to be allocated. Aboriginal populations in Alberta 
tend to live in more rural, or remote, areas of the province meaning access to 
specialists may be less than for those living in urban centres (Statistics Canada, 2012). 
Thus, data on prevalence can lead to better connections between family practitioners 
in rural areas and specialists in urban areas. From a research perspective, it may help 
to identify subsets of the MS population for trials on new therapies or management 
strategies. 
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 It has been suggested that First Nations with MS have a more aggressive form of 
the disease, but AHD does not have information to allow for an assessment of disease 
severity or progression (Misattari et al., 2001). While AHD can provide evidence on 
disease prevalence, it cannot directly measure disease severity. Either proxies, based 
on health service use, or direct measurements would be needed. AHD, by itself, is not 
sufficient for determining if Aboriginal populations do have a more aggressive form of 
the disease. 
 Having an administrative process that captured information on First Nations 
status provided strength to the study. It removed the need to recruit people into the 
study, which may have been a challenge given the low frequency, and the high 
proportion of First Nations living in rural, or remote, areas of the province. The 
population-based nature of the study allowed for a direct comparison between First 
Nations and the general population. 
 While the validity of the diagnosis is a common limitation of studies using AHD, 
this study did use a case definition algorithm and had findings that were consistent 
with other studies (Warren & Warren, 1992; Warren & Warren, 1993; Klein et al., 
1994). It is not known if First Nations with MS utilize health services differently than 
other MS cases. First Nations are more likely to live in rural and remote locations, and 
may not have the same access to health services, particularly specialty services. This 
could limit, or delay, the discovery of MS among First Nations leading to lower 
prevalence estimates. However, given the nature of MS, it is unlikely health service 
access would fully explain the difference in prevalence. 
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7.3.4 Publication 10 
Svenson, L.W., Warren, S., Warren, K.G., Metz, L.M., Patten, S.B., & Schopflocher, D.P. 
(2007). Prevalence of multiple sclerosis in First Nations people of Alberta. 
Canadian Journal of Neurological Sciences, 34, 175-180. 
Link: http://dx.doi.org/10.1017/S0317167100006004  
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7.4 Assessing Vaccine-Associated Febrile Seizure Risk – Publication 11 
7.4.1 Study Summary and Critique – Publication 11 
Publication 11 (MacDonald et al., 2014) examined the risk of a child developing a 
febrile seizure following administration of measles-mumps-rubella-varicella (MMRV) 
vaccine relative to same-day administration of separate measles-mumps-rubella and 
varicella vaccines (MMR+V). The design was a retrospective population-based cohort 
covering the period 2006 to 2012. It estimated the relative risk for children receiving 
the MMRV from 2010 to 2012, and for children receiving MMR+V from 2006 onward 
via linkage of multiple databases.  
Pre-licensure clinical trials had found a safety profile, for MMRV, similar to that 
found for MMR+V, except for an increased incidence of fever (Czajka et al., 2009; 
GlaxoSmithKline, 2014). In 2010, Klein et al. reported an increased risk of a febrile 
seizure associated with the use of MMRV vaccine in the United States, when compared 
to the administration of MMR and varicella as separate vaccines. The U.S. study found 
there was one additional seizure event for every 2,300 doses of MMRV vaccine 
administered. The MMRV product used was in the U.S. (ProQuad®) was different than 
what was being used in Canada (Priorix-Tetra®) and some European countries. The lack 
of evidence on febrile seizure risk for Priorix-Tetra® was a catalyst for the current study.  
Health insurance registry data was used for demographics, and to censor the 
data for anyone moving out of the province or dying. Immunisation data were 
extracted from a population-based immunisation repository which was used to 
determine which vaccines were administered and when. Data from hospitalisations, 
outpatient clinics, and physician visits were then used to define not only febrile 
seizures, but also comorbid conditions that may influence a seizure risk. The results 
were consistent with that of Klein et al. (2010), finding both an increased risk of a 
febrile seizure (one additional seizure for every 2,841 doses administered) and a similar 
risk window (7 – 10 days). At the time the paper was in press, Schink et al. (2014) 
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published a paper showing a febrile seizure risk with MMRV vaccine, used in Germany, 
of one additional seizure for every 2,747 doses administered. 
This study was able to demonstrate that the linkage of multiple administrative 
health databases, combined with a longitudinal design could be used to augment 
passive surveillance programs for adverse events following immunisation. Also, it 
demonstrated the value of AHD as a novel way to examine risks that may not have 
been included in clinical trials. The clinical trials assessing the efficacy and safety of the 
vaccine were underpowered to detect the risk found in this study. The results 
contribute to the evidence base on vaccine safety, and provided front-line public 
health practitioners with reliable evidence that could be used in discussions with 
parents about the risks and benefits of vaccination. It also lays the groundwork for 
providing assurances that vaccine safety is well monitored. 
 It is possible that children who had a febrile seizure may not have been taken for 
medical care. Given the study was focused on children under two years of age, it is 
believed that a seizure would be sufficient to generate parental concern to prompt a 
visit. It was not possible in this study to examine medical charts as part of the analysis, 
but given seizure risk was evaluated pre- and post-vaccination, the relative risk 
measures should remain unbiased. In support of this, Klein et al., (2010) conducted a 
chart review as part of their assessment of febrile seizure risk and found a modest 
change in their relative risk measure. Their chart review showed their estimates were 
conservative which would under estimate the actual risk. 
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7.4.4 Publication 11 
MacDonald, S.E., Dover, D.C., Simmonds, K.A., & Svenson, L.W. (2014). Risk of febrile 
seizures after the first dose of measles-mumps-rubella-varicella vaccine: a 
population-based cohort study. Canadian Medical Association Journal, 186, 824-
829. 
Link: http://www.cmaj.ca/content/186/11/824.abstract  
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7.5 Summary 
 This chapter highlighted three publications that contributed to a better 
understanding of risk and outcomes. The first two examined the role of ethnicity as a 
risk factor for MS, while the third evaluated the risk associated with a new vaccine. 
While each had their limitations, they generated results that were consistent with 
other research. 
 The comparison of an ecological study with that of a case control study suggested 
the relationships found in other studies on ethnicity might have been attributed to an 
ecological fallacy. Despite this, it also demonstrated the value of ecological studies in 
better understanding the distribution of a health event, and possible explanations for 
the geographic distribution observed. In addition, the data can also be used to guide 
the planning of services for individuals living with MS. It allows clinicians to offer more 
patient-centred care, may contribute to conversations about familial risk, and may 
influence patient satisfaction, perceived benefits, and compliance with disease 
management services (Buchanan et al., 2010; Kim et al., 2014). 
Publication 11 (MacDonald et al., 2014) was the first Canadian study to look at 
the risk of a febrile seizure associated with MMRV vaccine (Law et al., 2014). RCTs 
designed for vaccines generally include assessment of adverse events, but may be 
underpowered to detect rare, but important adverse events. In this case the initial 
RCTs that demonstrated the efficacy of the vaccine were underpowered to detect this 
adverse event (GlaxoSmithKline Inc., 2014). This allowed for a relatively inexpensive 
and efficient way to assess the effectiveness of interventions, and determine if they 
should continue, or if further study is warranted (Gallagher, 2004).  
A better understanding of risk and outcomes of new interventions can help to 
inform health policy development, research agendas, adverse event surveillance, and 
provide front line health professionals with information when advising patients and 
their family members. In the next chapter, the role AHD plays in the creation of health 
policy will be explored.  
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Chapter 8: Supporting Health Policy Development 
8.1 Introduction 
The application of research findings to ‘real world’ situations is the goal of many 
researchers. A general theme with the evolving use of AHD is to ensure its use supports 
the development of evidence-based policies and actions. Cooke et al. (2013) argued 
that AHD could have a significant impact on practice. They do caution that researchers 
must be careful in the data selected and approach to avoid developing biased results, 
but that a well-designed study can lead to valuable improvements in practice. 
Once a policy decision has been made and implemented, it becomes important 
to determine if the policy had the intended outcome. Also, it becomes important to 
understand if there were any untoward outcomes. In this chapter, Publication 12 
(Russell et al., 2014) will be used to as an example for assessing the impact of the 
introduction of a new vaccine for preventing chickenpox on the incidence of shingles, a 
condition that manifests from the same varicella virus that produces chickenpox.  
8.2 Informing Health Policy – An Example with Varicella Vaccination 
8.2.1 Study Summary and Critique – Publication 12 
 Varicella zoster virus is responsible for chickenpox in children and herpes zoster, 
also known as shingles, in adults. Varicella vaccines were licensed for use in Canada in 
1998 with the province of Alberta introducing varicella vaccine, for the prevention of 
chickenpox, to the publicly funded immunisation program in 2001 (Russell et al., 2005). 
Brisson et al. (2003) have suggested that the introduction of varicella vaccine programs 
for children may result in an increased incidence of shingles among older individuals 
due to a lack of immunological boosting that comes from exposure to varicella virus.  
 With the introduction of any public health intervention, it is important to 
understand any potential impact, whether positive or negative, on population health. It 
was unclear what the potential impact of childhood varicella immunisation would be 
on the incidence of shingles. Two studies, with results from Canada and the United 
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Kingdom, had observed increases in the incidence of shingles prior to the introduction 
of vaccine (Russell et al., 2007; Brisson et al., 2001).  
 To assess the impact of varicella vaccine on the incidence of shingles, data over a 
10-year period were examined using a quasi-experimental design. While the approach 
was observational in nature, there was an intervention (vaccine introduction), and the 
intervention was not controlled, nor initiated by the researchers. Changes in the 
incidence of shingles were studied using three time periods – the period prior to the 
introduction of vaccine (1994-1998), the period when it was available privately (1999-
2001), and the period when it was publicly funded (2002-2010). 
 Using Poisson regression models, the study found the incidence of shingles had 
increased over the entire study period, and the presence of one or more comorbidities 
was associated with an increased incidence of shingles. There was also a statistically 
significant decrease in the incidence rate among children less than 10 years of age.  
 An increasing rate of shingles among older individuals was a trend that began 
prior to the implementation of the immunisation program. As this appeared to be a 
continuation of the trend that pre-dated the introduction of the vaccine, it was not 
possible to assess the contribution of the immunisation program to this increasing 
trend. While it was not possible to fully assess the impact of the immunisation program 
on overall rates of shingles, we were able to show there were decreases in the 
incidence of shingles among children demonstrating the value of AHD for assessing 
outcomes related to healthcare interventions. 
 Alberta has a publicly funded, universally available health care system that is less 
prone to selection bias that may be seen from data that are specific to private 
insurance plans. The publicly funded aspect of the system reduces financial barriers 
from accessing services. The study also included comorbidities that may impact on the 
probability of developing shingles as a means of explaining variance seen in the 
statistical models. We also separated incidence shingles events from recurrent by using 
a 180-day buffer. Any shingles diagnosis received more than 180 days from the initial 
shingles diagnosis was considered a recurrent event and any less than 180 days was 
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considered part of the initial episode. This ensured a more accurate classification of 
incident and recurrent cases.  
 Limitations of this study primarily centred on the classification of cases and the 
potential for misclassification. Only a single record with shingles recorded was 
sufficient to be deemed a case. This could result in a higher number of false positive 
cases. Such a bias could skew results, and make it difficult to know if the trends 
observed were real, or an artefact of how cases were identified. However, Yawn et al. 
(2011) compared administrative health data and medical charts for shingles, and found 
that a single shingles code was correct approximately 85% of the time, and that AHD 
tended to underestimate the incidence of shingles. This means that any 
misclassification bias would be to err away from an increasing trend in shingles 
incidence.  
 With the introduction of any new vaccine awareness among health professionals 
usually increases, and this may impact on how physicians diagnose and report on cases 
of disease. This may also introduce a bias in reporting resulting in more cases being 
reported in the period after vaccine introduction than the period prior to introduction. 
It would be expected that this would bias towards increased reporting, but it is not 
possible to determine what impact, if any, this would have on the identification of 
cases. Any cases of shingles that did not seek medical care would be missed. This 
would bias results towards seeing no increase in shingles rates both before and after 
public funding. 
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8.3 Summary 
This paper represented a novel approach to trying to assess the risk of a health 
condition increasing as the result of the introduction of an immunisation program 
designed to prevent another condition. This type of evidence is valuable to policy 
makers in making decisions to fund, or defund, a program as well as their ability to 
respond to elected officials and the general public. Front line practitioners, when 
speaking to risks associated with the vaccine, can also use the information. The 
program appears to have contributed to a decrease in shingles incidence among 
younger age groups, but it was not possible to fully assess the overall impact of the 
varicella immunisation program on the incidence of shingles. Despite not providing 
definitive results, the study demonstrated a novel way of monitoring policy decisions. 
It also implies that more than AHD is needed to address some questions. Simply put, 
AHD provides valuable information on what is happening, but may need to be 
augmented with other approaches to provide a more fulsome understanding. 
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8.4 Publication 12 
Russell, M.L., Dover, D.C., Simmonds, K.A., & Svenson, L.W. (2014). Shingles in Alberta: 
Before and after publicly funded varicella vaccination. Vaccine, 32, 6319-6324. 
Link: http://www.sciencedirect.com/science/article/pii/S0264410X13012498  
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 Chapter 9: Methodological Critique 
9.1 Introduction 
 Chapters 3 through 8 provided a summary of each paper included in this thesis. 
This chapter will focus on the methodological aspects of each publication by grouping 
them together by study design. Strengths and limitations of the designs will be 
discussed. The emphasis will be on highlighting both strengths and weaknesses that 
were common across multiple papers. 
9.2 Cross-Sectional Designs  
Cross-sectional studies are a form of observational study that include either the 
entire population, or a representative sample of the population, with the goal of 
describing the population at a point in time (Rothman & Greenland, 1998). The 
purpose of a cross-sectional design is descriptive and usually there is no hypothesis 
being tested (Levin, 2006a). Cross-sectional studies typically collect exposure and 
outcome data at the same time, so the temporal relationship cannot be determined. 
However, they may provide clues for the development of hypotheses that could be 
tested with an experimental design (Rothman & Greenland, 1998; Levin, 2006a).  
Publications 1 (Svenson, 1990), 2 (Svenson, 1991), 4 (Yiannakoulias et al., 2003), 
7 (Svenson et al., 1999), 8 (Patten et al., 2007), and 10 (Svenson et al., 2007) were all 
population-based observational studies using a cross-sectional study design. While the 
approach for each study was appropriate to the given research questions, cross-
sectional studies come with strengths and limitations that need to be considered when 
interpreting findings. 
9.2.1 Cross Sectional Designs – Strengths  
There are general advantages to cross-sectional designs that apply to each 
study presented. These include data access was inexpensive; data were population-
 65 
based allowing for estimations of prevalence; data could be used to support priority 
setting; data could be used to support health system planning; and development of 
aetiological hypotheses (Levin, 2006a). In addition to these advantages, the 
population-based nature of AHD reduces the risk of both selection and recall bias. Also, 
there was no need to contact patients or their family members to obtain the 
information. 
Each study included strengths that were unique to the study. Publications 1 
(Svenson, 1990) and 2 (Svenson, 1991) benefitted from the completeness of each data 
source, consistency in coding, accessibility of the data, and the data were continuously 
collected over time. For publications 4 (Yiannakoulias et al., 2003) and 8 (Patten et al., 
2007), an additional strength was the ability to link unique individuals across each 
source of AHD. This allowed for a more thorough understanding of patient interactions 
with the health system and to attach attributes of interest to the individual. Publication 
7 (Svenson et al., 1999) demonstrated the value of AHD for capturing data on rare 
health events and Publication 10 (Svenson et al., 2007) showed the advantage of 
having additional demographic information allowing for the assessment of a health 
event among a particular subgroup in the population (First Nations). While not a 
specific strength of a cross-sectional design, these could be considered as strengths in 
that they were non-intrusive ways of assembling the data. 
In addition to the above strengths unique to each study, there were general 
strengths that applied to each. The data were population based, reducing issues of 
selection bias. There is no need to contact individuals, which represented an efficient 
and cost-effective approach for collecting data. This approach was also free from issues 
of recall bias. The population-based level of the analysis resulted in large sample sizes 
that allowed for more precise point estimates, and greater confidence that the studies 
represented meaningful results. 
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9.2.2 Cross Sectional Designs – Weaknesses 
There were general limitations that applied to Publications 1 (Svenson, 1990), 2 
(Svenson, 1991), 4 (Yiannakoulias et al., 2003), 7 (Svenson et al., 1999), 8 (Patten et al., 
2007), and 10 (Svenson et al., 2007). It was not possible to make any links with causal 
factors. Cross-sectional data are a description of the time period under investigation, 
and the situation may change if another time period is examined. However, the data 
can be used to generate hypotheses about causal relationships. For Publications 2, 4, 7, 
and 8 it was not possible to separate incident and prevalent cases of disease. For 
Publication 10, this limitation did not apply as a case definition algorithm was applied. 
This allowed incident and prevalent cases to be distinguished.   
Other limitations were specific to each study more so than a limitation to the 
study design. For Publications 1 (Svenson, 1990) and 2 (Svenson, 1990) there was a lack 
of information on birthplace, places of residence, age of disease onset, severity of 
illness, and bias in vital event recording of underlying cause of death. Underreporting 
for the underlying cause of death may lead to under estimations of disease prevalence, 
and be biased towards the more severe presentations of disease. There may be other 
issues with mortality data that could compromise the interpretation of any findings. 
These include personal preference on where to die, which could impact the 
assessment of geographic distribution; not all deaths result in an autopsy, so important 
causes of death may go missed; and vital statistics agencies typically do not confirm the 
accuracy of the information submitted, meaning coding errors could go undetected 
(Nielsen et al., 1991; Schnatter et al., 1990). These limitations, if not considered, could 
lead to misinterpreting evidence on disease burden, which may in turn negatively 
impacts priority-setting and resource allocation.  
It is also possible to over-estimate disease frequency should criteria for case 
identification be too lenient or inclusive. For studies of outcomes, the more stringent 
criteria that underestimates cases will provide meaningful results as each case included 
will have a higher probability of being a true case. If the study is focused on the overall 
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use of the health care system, then over or under estimation of disease frequency may 
not result in significant impacts, as they will represent meaningful information from a 
planning or resource allocation perspective. In any retrospective analysis of health 
system use, the accuracy of the diagnosis can be less important as it is the use of 
services that is the unit of analysis. While these represent important considerations 
when interpreting results, the strengths when combined with the consistency of results 
with other studies, demonstrate the advantages of using AHD outweigh the 
weaknesses. 
9.3 Cohort Study Designs 
 Levin (2006b) defines a cohort, or longitudinal, study as one where a group of 
individuals is studied over a period of time. Longitudinal studies may be prospective or 
retrospective in nature. Cohort studies can be open with people moving in and out of 
the study or closed where a fixed population is followed with only exit from the cohort 
permitted. An advantage of this approach over cross-sectional designs includes being 
able to examine the temporal relationship between an event and an outcome. Also, 
cohort studies tend to have less potential for bias than other designs, but still may be 
vulnerable to issues of confounding. When primary data collection is done, cohort 
studies can be cost-prohibitive, as they generally need large sample sizes and long 
follow-up periods. This also means they are also not well suited for the study of rare 
events. Publications 3 (Robertson et al., 1998), 5 (Yiannakoulias et al., 2007), 6 
(Yiannakoulias et al., 2004), and 11 (MacDonald et al., 2014) were all population-based 
retrospective cohort studies. The strengths and limitations of the cohort approach for 
these publications will be discussed in the following sections.  
9.3.1 Cohort Design Strengths 
 Publications 3 (Robertson et al., 1998), 5 (Yiannakoulias et al., 2007), 6 
(Yiannakoulias et al., 2004), and 11 (MacDonald et al., 2014) each used multiple AHD 
sources to assess outcomes. They also shared the following general strengths: 
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avoidance of recall bias, no need to contact the families of cases, large population-
based sample size ensuring adequate statistical power, low cost compared with 
primary collection methods, and generalisability of the results due to the population-
based nature of the data. The longitudinal design made it possible to look at temporal 
associations between the exposure under study and the outcome of interest. The use 
of AHD provided an efficient means of keeping track of demographic information such 
as address allowing for an accurate assessment of geography. 
9.3.2 Cohort Design Limitations 
 There were limitations associated with this design and AHD that need to be 
considered when evaluating Publications 3 (Robertson et al., 1998), 5 (Yiannakoulias et 
al., 2007), 6 (Yiannakoulias et al., 2004), and 11 (MacDonald et al., 2014). First, the 
diagnostic information used was not validated. While this does not mean the data are 
invalid, it does mean that there may have been misclassification of cases. Also, it was 
not possible to know how complete the data were, and if there was a bias on health 
seeking behaviours that may have resulted in a diagnosis being missed or delayed. The 
criteria used by physicians for diagnosis is not captured within AHD making it difficult 
to discern those with a diagnosis and those being investigated for a given diagnosis. 
9.4 Ecological Study Design 
 An ecological study is a form of observational study where the unit of 
observation is the group, and not the individual (Rothman & Greenland, 1998; Levin, 
2006c). Levin (2006c) states that an ecological design is used when: there is a need to 
monitor population health; large-scale comparisons are to be made; the purpose is to 
assess population level risk factors and disease incidence; and when individual level 
measurements are not available. Publication 9 (Warren et al., 1996) used a 
geographical ecological design. It also compared results with a case-control study as a 
means of reducing potential confounding such as the risk of an ecological fallacy.  
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9.5 Quasi-Experimental Design 
 A quasi-experimental design is one that sits between an observational study 
and an experimental study. It can be considered a non-random intervention study with 
pre- and post-test components used to determine the impact of an intervention or 
program (Harris et al., 2006; Polit & Hungler, 1987).  
 Publication 12 (Russell et al., 2014) was a form of quasi-experimental design as 
it looked at whether the implementation of a new vaccine (i.e., varicella vaccine) would 
have an impact on disease (i.e., herpes zoster) incidence. The strength of the approach 
was that it was population-based, and used multiple databases for case ascertainment. 
The study also included comorbidities that may impact on the probability of developing 
shingles as a means of explaining variance seen in the statistical models used. Quasi-
experimental designs tend to offer good external validity as they are assessing 
interventions that have happened in the ‘real world’.  
With quasi-experimental designs, it is not possible to control as many factors as 
in an experimental design. Also, there was no control group as the intervention was 
population based. This limits the ability to make assertions about the causal nature of 
the data. However, the observational nature of the study does allow for an 
understanding of any potential impacts, whether positive or negative. The 
implementation of policies, or programs, provide a natural experiment whereby AHD 
can be used to identify whether the goals of the program were met and if any risk was 
created as an unintended consequence. This could lead to the development of 
hypotheses that may be tested using experimental designs. 
9.6 Summary 
 Each design highlighted in the thesis has its own inherent strengths and 
weaknesses. This is not unique to AHD, but to any study. While limitations exist, the 
thesis has demonstrated that the strengths of AHD outweigh the limitations. Despite 
the limitations noted, there was consistency in findings with other studies that works 
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to add confidence to the value of AHD. AHD represent a valuable data source for 
understanding disease burden.  
 Each paper included in the thesis had consistency in their strengths. These 
included: the population-based nature of the data; no recall bias; cost-effective access 
to the data; data collection was non-intrusive; and the data were readily available. 
Other strengths were unique to specific studies included.  AHD allows for long duration 
of follow-up without being resource prohibitive (see Publications 3, 5, 6, and 11) 
(MacDonald et al., 2014; Robertson et al., 1998; Yiannakoulias et al., 2004; 
Yiannakoulias et al., 2007). Another strength, linking multiple databases, was specific 
to all publications except Publications 1 and 2. These strengths of AHD combined with 
the use of appropriate research designs have demonstrated the value of AHD for 
quantifying burden of disease. 
 There were also limitations specific to the use of AHD highlighted in Chapter 2. 
While these general limitations also applied, it was possible to overcome some of the 
limitations. For example, Publication 9 used multiple designs and compared AHD with 
case-control data to address the potential for an ecological fallacy (Warren et al., 
1996). Publication 11 linked multiple databases together to ensure the analysis could 
be adjusted for health events that might influence the outcome of interest (MacDonald 
et al., 2014). While limitations need to be considered, creative use of the data 
combined with good study design may help to mitigate perceived and actual risks to 
the validity of findings. Overall, the 12 papers have established that AHD can and do 
play a valuable role for understanding the burden of illness. 
The next chapter will provide a summary, recommendations for future 
research, and concluding remarks. 
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Chapter 10: Summary, Recommendations, and Conclusions 
10.1 Summary 
 The overall aim of the thesis was to demonstrate how AHD has evolved to 
become a valuable source of data for quantifying disease burden. Through a critical 
review of 12 publications, the evolution of the use of AHD has been shown over 25 
years. Each paper was selected to demonstrate a concept as well as show a unique 
contribution to better understanding the use and value of AHD. The use has evolved 
from utilisation measures to descriptive epidemiological studies to more sophisticated 
study designs that allowed for the assessment of risk and outcomes. Initially, there 
were views that AHD was of limited value for understanding disease burden due to 
concerns over the integrity of the data. However, descriptive studies on the incidence 
and prevalence of chronic conditions have generated estimates and patterns 
consistent with studies using primary data collection strategies. They have also 
supported the development of aetiological hypotheses. This was demonstrated by the 
examination of mortality and hospitalisations attributed to Parkinson’s disease 
(Svenson, 1990; Svenson, 1991). It was further advanced by looking at parental 
ancestry of multiple sclerosis by including AHD and case-control data to tease out the 
relationship of ancestry and MS risk while also addressing the possibility of an 
ecological fallacy (Warren et al., 1996). The consistency of findings between the two 
embedded designs worked to strengthen both approaches. 
The application of case definition algorithms, with a person-oriented approach, 
has allowed for the creation of accurate estimates of disease burden. The estimates 
tend to err on the side of specificity when early concerns were that the error would 
lead to an increase in false positive cases. By adding a longitudinal component, it 
becomes possible to accumulate evidence at the person level that strengthens the 
likelihood that a case of a disease is truly a case. It also allows for a better 
understanding of outcomes. The concept that a case definition, with inclusion and 
exclusion criteria, resulted in reliable measures of burden was shown through the 
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examination of the birth cohort prevalence of cerebral palsy in Alberta (Robertson et 
al., 1998). This was a novel approach at the time of the study. 
In addition to the use of a longitudinal approach to assigning cases status, both 
geographical considerations and the concept of run-in periods were added as 
important considerations. Differences in the coding of stroke events between urban 
and rural health care facilities highlighted the value of geography and the availability of 
diagnostic technology (Yiannakoulias et al., 2003). This contributed to a better 
understanding of how the specificity of a diagnosis is influenced by where the patient is 
diagnosed. Patient movement following a diagnosis was shown to not have an impact 
on geography-based incidence and prevalence estimations (Yiannakoulias et al., 2007). 
The concept of a run-in period was also a novel contribution as it aided in 
differentiating between incident and prevalent cases of disease (Yiannakoulias et al., 
2007). 
 It has also been shown that AHD are valuable for the identification of people 
with rare conditions where primary data collection mechanisms are either too costly or 
are drawn from biased samples. AHD represents a cost-effective means of determining 
the burden of rare conditions. Assessing the prevalence of motor neurone disease, the 
first population-based study in Canada, was used to highlight the value of AHD for 
studies related to rare health conditions (Svenson et al., 1999).  
AHD acts as an efficient source of evidence for understanding the presence of 
comorbidities. Given comorbidities represent complexities for the treatment and 
management of chronic conditions, understanding their frequency provides needed 
evidence for health policy development, resource allocation, and practice or service 
development. The value of AHD for assessing comorbidities was demonstrated by 
looking at the presence of affective disorders among individuals with MND (Patten et 
al., 2007). This represented a unique approach in Canada at the time of the study. 
 AHD has been shown to add value for understanding the impact of policy 
decisions through an examination of ‘real world’ situations. The example provided 
looked at the potential negative impacts following the introduction of a new vaccine to 
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an immunisation program (MacDonald et al., 2014). AHD has been shown to be 
valuable to assess outcomes in ways that RCTs cannot. At the population level these 
outcomes can become significant. RCTs play an important and valuable role in 
understanding the efficacy of a new intervention relative to existing practice, while 
AHD plays an important and valuable role in understanding the population-level 
impacts, and a better understanding of the effectiveness of the new intervention. The 
thesis has shown that the use of AHD can augment the evidence from primary data 
collection studies. 
 The development of evidence in the health sector is created to inform and drive 
action. The analysis of AHD provides the necessary support to either directly or 
indirectly influence practice. For example, assessing the risk of a vaccine has both an 
indirect and direct impact on practice. At the indirect level, it informs health policies 
and at the practice level it provides health professionals with the information they 
need to decide on the best options for patients as well as providing an opportunity to 
inform and educate (MacDonald et al., 2014; Russell et al., 2014).  
 In addition to the above examples, the papers included in this thesis have also 
shown that AHD can be used in novel methodological ways to understand both disease 
burden and risk. For example, Yiannakoulias et al. (2004) placed physicians in both the 
role of a health care provider and as a patient. The feasibility of doing this study 
through primary data collection would have been limited and costly. Thus the 
population-based nature of the data as well as not having to interview study subjects 
allowed for an efficient way of quantifying and understanding both burden and risk. 
While the thesis has highlighted how AHD can be a source of valuable evidence, 
it has also highlighted some important limitations associated with the use of AHD. 
These limitations can be used to develop recommendations for future research as a 
means of improving not only data quality, but also the value of any findings. With 
continued and increasing use, it is important to ensure the data can continue to 
support research in a meaningful way. 
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10.2 Recommendations for Research 
There are a number of avenues for future research involving the use of AHD. 
Recommendations for future research will focus on AHD and not a specific disease or 
group of diseases. Regardless of the topic under study, researchers should start by 
understanding what AHD they have access to, how it was collected, the scope of the 
population included, and whether it is the right option for the study question.  
The risk of having biased results, when using AHD, can be minimized by 
providing thorough descriptions of the data used, reporting on the accuracy of 
diagnostic of procedural codes used, distinguishing between statistical and clinical 
significance, understanding the time dependent nature of the data, and exploring the 
influence of clustering within the data on the study conclusions (van Walraven & 
Austin, 2012).  
10.2.1 Validation Studies 
An important aspect to understanding the value of any data source is to 
understand its validity and reliability (McPheeters et al, 2013; van Walraven et al., 
2011). The introduction of errors may lead to one of two negative issues. First, it may 
lead to the adoption of evidence that is wrong as a result of not validating the data. 
Second, for studies where the findings are valid, there may be difficulty with adoption 
should people have concerns with validity. 
Validation studies need to examine evidence drawn from multiple AHD sources 
and then determine the accuracy of the final assignment of disease status. Researchers 
need to carefully evaluate any algorithm in light of the data sources available to them. 
As part of the validation, there is a need to understand the impact of the deployment 
of new technologies as these may influence the diagnostic decision making process. 
Access to these technologies also needs to be assessed. Are there urban and rural 
differences in access or the criteria used for a diagnosis? Are there factors that create 
an inequity to accessing health services that may influence when and how a diagnosis 
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is provided? Are there issues with the completeness of case ascertainment that are 
related to administrative practices or data entry error? 
10.2.2 Systematic Reviews 
There is a need for systematic reviews of the evidence on the validity and 
reliability of AHD. This review should include the assessment of individual databases, 
performance of case definition algorithms, impact of population migration, 
immigration and emigration, availability and accessibility of health care professionals 
and facilities, completeness of coverage of AHD within different jurisdictions, 
population attributes, and administrative practices that guide the collection of the 
data. There are numerous factors, beyond the incidence, prevalence, or severity of 
disease, that influence health service use. This in turns has an influence on the 
collection, completeness, and reliability of findings based on AHD.  
10.2.3 Evaluating New Technology and Data Sources 
 The healthcare system is complex and ever changing. New technologies can 
assist with providing a more accurate and timely diagnosis. The timing of the 
introduction of new technologies will have an influence on AHD-based studies. It will 
change the accuracy of the data over time, and algorithms used for case identification 
may not work across all time periods under study. As such, it is important to 
understand how to adapt approaches to ensure the integrity of the conclusions from 
any study. 
 Not all data collected within any given health system will be immediately 
available to researchers. When new data sources become available and can be linked 
to other data, this drives a need to examine the impact of the new data. In essence, it 
means continually refining approaches as new data becomes available. New data 
sources offer opportunities to improve the value of AHD and need to be systematically 
assessed. 
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 There is a need to explore the methods for linking AHD with data collected from 
other study designs. Linking of data can help to fill gaps that one data source cannot 
address on its own. For example, linkage of RCT data to AHD would help to better 
understand gaps that occur between the efficacies found in the RCT, and the 
effectiveness in the community. This approach would provide a transition from the RCT 
to a natural setting. AHD offers population-based ‘real world’ perspectives that RCTs 
are unable to provide.  
10.2.4 Leveraging New Methods and Emerging Trends 
 The emergence of the concept of ‘big data’ has led to new approaches to 
managing large structured and unstructured data. There is a need to determine how to 
apply the general approaches used for ‘big data’ and data visualisation to AHD-based 
research. Initially this needs to focus on the how to best link AHD to non-traditional 
sources of information, and to evaluate the value of such linkages.  
Big data analytics in healthcare can be considered a growing and nascent field. 
There is need to develop methods for combining and mining AHD. While ‘big data’ may 
help to provide answers to clinical or policy questions more quickly, the data and 
methods need to be evaluated to ensure the rapid output is reliable and valid, and 
does not negatively impact decision-making. Research focused on new methods for 
data visualization will provide opportunities for hypothesis generation. There is a need 
to ensure the use of new technologies to go beyond descriptive or predictive analytics 
to the development of explanatory models that could lead to value insights that drive 
policy and practice. 
10.2.5 Ensuring Generalisability 
 The context in which research is conducted plays an important role in the 
interpretation of findings. Any research on the validity or reliability of AHD needs to 
consider if the results can be generalised beyond the location of the study. Do 
validation studies in one country, or jurisdiction within a country, apply to others? 
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Under what conditions do the results generalise? What are the factors that can 
improve the generalisability of findings from one study to the next? These represent 
questions that help to ensure the reliable use of AHD. What works well in one context 
may not work in another. Understanding this will help reduce the risk of contributing 
poor evidence. Systematic reviews may help to answer some of these questions and 
should be explored. Also, validation studies should be conducted across countries or 
across administrative areas (provinces or states) within a country, and correlate results 
from various databases and approaches. The greater the consistency in findings across 
locations, the more confidence researchers can have in the results. The papers 
critiqued have shown that while the data for ten were from a single Canadian province, 
when compared to studies from other jurisdictions there were consistent findings. For 
example, estimates of birth cohort prevalence of cerebral palsy were consistent with 
results from international studies (Murphy et al., 1993; Robertson et al., 1998; Stanley 
& Blair, 1991). The risk of febrile seizures following the introduction of MMRV vaccine 
were consistent, both in terms of magnitude and timing, as studies from the Unite 
States of America and Germany (Klein et al., 2010; MacDonald et al., 2014; Schink et 
al., 2014). This suggests that the findings of studies based in one location may 
generalise well to others. 
10.3 Implications for Practice, Policy Development and Resource Allocation 
 The papers presented have implications for practice, policy development, and 
resource allocation. They have shown that AHD can be used to quantify the burden of 
disease, which contributes to setting priorities, and understanding health system 
burden. Also, an understanding of the distribution of disease helps to generate 
hypothesis about aetiological factors, which, in turn, contributes to our understanding 
of how to reduce the risk or burden of disease.  
AHD is a valuable tool for identifying rare conditions, as information is often 
lacking to support the needs of policy makers and practitioners. Understanding the 
location of people with chronic conditions helps to ensure there are adequate 
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resources allocated to address population needs. This would include informing how 
many health professionals are needed, the type of training required, whether facilities 
are needed, and other supports. 
 The thesis has also shown that AHD can be used to augment other data sources 
and to evaluate interventions. Two examples were provided related to immunisation 
programs with both having policy and practice implications. By monitoring the impact 
of new programs and risks associated with new interventions, it becomes possible to 
develop good public health policy, and provide the public with assurance that systems 
are in place to protect health. From a practice standpoint the examples showed that 
AHD could quantify risk in a way that allows health professionals to speak honestly and 
with confidence about the safety of the intervention, what to watch for following the 
intervention, and time period to which the risk is greatest. This type of evidence allows 
health professionals to be well informed, and to have meaningful conversations with 
patients and colleagues. 
10.4 Conclusions 
 By understanding both the strengths and limitations of AHD, we improve our 
ability to use these data effectively. AHD represent a rich source of data with great 
potential. The development of evidence using different methods, particularly when 
there are consistent results, works to strengthen our understanding of any given health 
issue. AHD have the advantage of covering nearly the entire population thus providing 
an opportunity to support stronger health system planning, policy development, and 
evaluation. Also, they lack many of the biases seen with other data sources making 
AHD a solid starting point for the development of hypotheses. 
 The thesis has highlighted the evolution of thinking and use of AHD as well as 
the application of novel methods. The 12 papers included in the thesis have 
demonstrated an evolution in the use of AHD and have clearly shown that AHD is 
valuable for quantifying the burden of illness. Each paper had results consistent with 
other studies that used either secondary or primary data collection. Also, there was an 
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increasing sophistication to the methods applied to AHD as well as the development of 
novel methods. These were used to increase the accuracy and, therefore, relevance of 
the findings. 
While there may be risks that decisions could be made in error because the 
data used was of insufficient quality to appropriately address the question, this is not 
unique to AHD. Where AHD are of sufficient quality and timeliness, they represent a 
cost-effective and efficient means for answering important questions about the health 
of the population, the development of health policies, evaluation of interventions and 
outcomes, and the allocation of resources. The use of AHD will continue to grow, but 
to make the most of any research study researchers will need to understand and work 
within both the limits and strengths of the data. Researchers need to evaluate the data 
sources available to them, and critically evaluate the applicability to the study 
question. 
The aim of this thesis was to highlight the evolution of thinking around the use 
of AHD and has shown that it can be used to accurately quantify the burden of illness. 
Strengths and weaknesses have been highlighted with the strengths outweighing the 
weaknesses. The 12 papers critiqued have shown that AHD can be used to provide 
reliable and accurate estimates of disease burden as well demonstrating value to 
understanding ‘real world’ applications of policy and practice. The data work to 
augment or compliment designs based on primary data collection. The evolution of the 
use of AHD has shown that robust measures of burden of illness could be developed 
and used. If this evolution had not occurred, it is possible that mortality data would 
have remained as the measure of choice for disease burden. As shown, mortality data 
are valuable, but tend to result in more biased estimates of disease burden. 
It has been demonstrated that AHD plays an important role in providing 
evidence to support the process of developing policies, monitoring impact of decisions, 
setting priorities, allocating resources, and ultimately informing practice. It represents 
an important and valuable resource for understanding population health and the use 
of health services. It has been demonstrated that AHD is of sufficient quality and value 
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to play a central role in the quantification of the burden of illness. Its continued 
evolution will work to improve data quality and the utility of these data for 
understanding the burden of illness and to better inform actions taken to improve 
health and quality of life.  
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Appendix C: Publication Citation Reports 
 The table below provides a listing of the number of times each article included 
in the thesis has been cited according to two sources – Web of Science® and Google 
ScholarTM. For both sources, the citation counts are as of July 21, 2015. The counts only 
include citations in peer reviewed professional publications and may be undercounts 
due to lags in the time from which a one of the papers was cited to when that 
information is available to the two query tools used. The publications are listed in the 
order in which they are cited in the thesis. 
Table C.1: Citation counts from each publication included in the thesis 
Number Publication Web of 
Science 
Google 
Scholar 
1 Svenson, L.W. (1990). Geographic distribution of 
deaths due to Parkinson’s disease in Canada: 1979 – 
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3 Robertson, C.M.T., Svenson, L.W., & Joffres, M.R. 
(1998). Prevalence of cerebral palsy in Alberta. 
Canadian Journal of Neurological Sciences, 25, 117-
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35 57 
4 Yiannakoulias, N., Svenson, L.W., Hill, M.D., 
Schopflocher, D.P., James, R.C., Wielgosz, A.T., & 
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disease diagnosis in the province of Alberta. Chronic 
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7 17 
5 Yiannakoulias, N., Schopflocher, D.P., Warren, S.A., & 
Svenson, L.W. (2007). Parkinson’s disease, multiple 
sclerosis and changes in residence in Alberta. Canadian 
Journal of Neurological Sciences, 34, 343-348. 
2 2 
6 Yiannakoulias, N., Russell, M.L., Svenson, L.W., & 2 6 
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Number Publication Web of 
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Schopflocher, D.P. (2004). Doctors, patients and 
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Public Health, 118, 527-531. 
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neuron disease: a population-based study. 
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(1996). Parental ancestry and risk of multiple sclerosis 
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5 5 
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Patten, S.B., & Schopflocher, D.P. (2007). Prevalence of 
multiple sclerosis in First Nations people of Alberta. 
Canadian Journal of Neurological Sciences, 34, 175-
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13 18 
11 MacDonald, S.E., Dover, D.C., Simmonds, K.A., & 
Svenson, L.W. (2014). Risk of febrile seizures after the 
first dose of measles-mumps-rubella-varicella vaccine: 
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Association Journal, 186, 824-829. 
5 12 
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publicly funded varicella vaccination. Vaccine, 32, 
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